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1. INTRODUCTION 
The human immunodeficiency virus 1 (HIV) causes lifelong infection that can 
lead to acquired immunodeficiency syndrome (AIDS) and death. In 2015, 
approximately 36.7 million people globally were living with the HIV/AIDS 
infection and although the infection is manageable using antiretroviral drugs, 
there are still major medical and socio-economic issues related to the infection: 
accessibility to treatment; side-effects; and risk behavior (www.unaids.org; 
www.who.int). Despite positive advances in treatment, research is ongoing to 
clarify the molecular mechanisms of HIV infection and find more effective 
treatment options.  
In addition to HIV, the hepatitis B virus (HBV) and hepatitis C virus (HCV) 
cause major health care issues around the world. All three infections can be 
transmitted via blood and therefore HIV/hepatitis co-infections are common 
among risk groups, such as persons who inject drugs (PWID). 
Despite repeated exposure, some individuals do not get infected with HIV, 
HBV, or HCV. Based on the frequency of their exposure, these individuals are 
defined as heavily exposed seronegative subjects or exposed seronegative 
subjects. Such individuals are interesting research subjects, because the reasons 
they are resistant are not fully understood. Only one gene variant, the 32-base 
pair deletion in the CC chemokine receptor 5 (CCR5) gene, is known to provide 
complete resistance against HIV R5-tropic viruses (Samson et al., 1996). As 
homozygosity of this mutation is quite rare, the reasons of resistance to HIV, 
HBV, and HCV viruses are still of great interest. The focus of HIV exposure 
studies has mainly been on sexually exposed individuals and data regarding 
persons who inject drugs (PWID) is limited. 
Factors protecting people from HIV and hepatitis infections can be divided 
into genetic, immunological, and viral factors. Genetic factors, such as single 
nucleotide polymorphisms and copy number variation, do not change during an 
individual’s life. However, immunologic factors are influenced by risk behavior 
and co-infections. Little is known about immunological aspects of HIV, HBV, 
and HCV co-infected/exposed PWID populations or how intravenous drug use 
itself influences immunological factors among PWID. 
The HIV epidemics is an especially important problem in Estonia, because 
Eastern-Europe is one of the few regions in the world where numbers of new 
HIV infections continues to increase (DeHovitz et al., 2014). The number of 
HIV infected and HIV/hepatitis co-infected individuals in Estonia is high, 
especially among PWID (Uusküla et al., 2007). The HIV virus transmitted in 
Estonia is very homogeneous, providing an opportunity to investigate the 
effects of genetic and immunological factors in terms of HIV and its co-
infections, without considering the viral divergence. Therefore, the aim of this 
study was to investigate genetic and immunological factors associated with 
HIV, HBV, and HCV infections and intravenous drug use among PWID. 
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2. REVIEW OF THE LITERATURE 
2.1. HIV, HBV, and HCV epidemics around the world 
The HIV epidemic is a major global health care problem, having already caused 
35 million deaths. Approximately 37 million individuals have HIV and about 
two million people became infected with HIV in 2015 (www.who.int). 
Although the majority of people infected with HIV live in Sub-Saharan Africa, 
Eastern Europe and Central Asia are one of the few regions where HIV 
incidence continues to increase (DeHovitz et al., 2014; www.who.int). HIV is 
not curable; however, it is controllable using antiretroviral treatment (ART), 
which has lowered the number of people reaching the acquired immuno-
deficiency syndrome (AIDS) stage and AIDS related deaths. In 2015 over 15 
million people received ART, however, 1.1 million people still died from AIDS 
related illnesses (UNAIDS, 2015; www.who.int). The main risk groups of HIV 
infections are commercial sex workers (CSW), men having sex with men 
(MSM), and persons who inject drugs (PWID, formerly known as intravenous 
drug users) (Beyrer, 2007). Although the risk of acquiring the HIV infection via 
intravenous drug use is higher than via heterosexual intercourse, the latter still 
accounts for 70% of new HIV cases worldwide (Mathers et al., 2008; Shaw and 
Hunter, 2012). 
The hepatitis C virus (HCV) is also a blood borne infection that has reached an 
epidemic proportion globally. HCV leads to acute and chronic infections that 
cause liver fibrosis, cirrhosis, or hepatocellular carcinoma in 15–30% of 
chronically infected individuals within 20 years (www.who.int). It is not exactly 
known how many patients recover from the HCV infection without treatment, but 
it could be approximately 15% (Di Bisceglie et al., 1991; Villano et al., 1999). 
Currently, about 130–150 million people globally are chronically infected with 
HCV (www.who.int). Although the infection is curable, access to treatment is low 
and approximately 500,000 people die annually from HCV related liver diseases 
(Lozano et al., 2012; Vos et al., 2015). The groups at risk of HIV and HCV 
infection are similar, including MSM, PWID, and hemophiliacs.  
The third infection common among groups at high risk of contracting HCV 
and HIV, is hepatitis B (HBV). Similar to HCV, HBV causes acute and chronic 
infections, and leads to hepatocellular carcinoma in ≈5–10% of infected indi-
viduals (www.who.int). Approximately 248 million people are chronically 
infected with HBV (Schweitzer et al., 2015). Although virus-specific treatment 
is not available, an effective vaccine is used in 99% of countries globally as part 
of a routine immunization plan (www.who.int). In the absence of vaccination, 
the HBV infection is self-limiting in over 90% of cases, and causes chronic 
infection mainly among infants and children (Liaw and Chu, 2009). The other 
groups of individuals at risk of chronic HBV infection are individuals with a 
compromised immune system, such as HIV positive patients, and PWID. 
HIV, HCV, and HBV have similar routes of transmission and co-infections 
are common, especially among risk groups such as PWID. It is estimated that 
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over two million people are HCV/HIV co-infected, of whom more than half are 
PWID (Platt et al., 2016). Co-infection status is important, because co-infection 
with HIV/HCV increases the pathogenic effects of both viruses. Among people 
with HIV, co-infection quickens disease progression, and co-infections 
involving HCV increase liver fibrosis (Eyster et al., 2016; Graham et al., 2001; 
Kovacs et al., 2008). In the case of HIV/HBV co-infections, the effects upon 
HIV progression are small; however, the possibility of a self-limiting HBV 
infection decreases and the risk of chronic hepatitis increases (Thio et al., 2002). 
 
 
2.2. HIV, HBV, and HCV epidemics in Estonia 
The first HIV-positive patient in Estonia was diagnosed in 1988. During the 
1990s, the prevalence of HIV remained low, spreading mainly through hetero- 
and homo-sexual contact (Ustina et al., 2001). An epidemic occurred in 2000, 
when the virus spread rapidly among the PWID population (Figure 1) (Laisaar 
et al., 2011). After the first outbreak – since 2001 – the number of newly 
infected individuals has decreased; however, Estonia remains one of the 
countries with the highest HIV incidence in Europe (DeHovitz et al., 2014; 
Laisaar et al., 2011). The main group affected by the epidemic were young male 
PWID, but over more recent years the situation has changed, with the number of 
new diagnoses increasing among individuals infected during heterosexual 
contact (Soodla et al., 2015). Currently, the age of newly infected individuals 
and number of women infected is increasing. Although sexual contact is one of 
the main causes of HIV transmission, the number of reported HIV cases is low 
among MSM (Laisaar et al., 2011; Soodla et al., 2015). Since the outbreak, the 
epidemic has been mainly localized in the northern part of the country (mainly 
the capital Tallinn and Eastern-Viru County).  
 
 
Figure 1. The incidence of HIV, HBV, and HCV infections in Estonia. The 
incidence per 100,000 persons of HIV is marked in red, acute HCV in green, and acute 
HBV in blue. The data are reported by the Estonian Health Board  
(www.terviseamet.ee/en/information.html). 
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The HIV epidemic in Estonia mainly involves HIV-1 CRF06_cpx viruses and to 
a lesser extent subtype A1 or recombinants between CRF06_cpx and A1 viruses 
(Adojaan et al., 2005; Avi et al., 2009, 2010). Similar to other Eastern European 
countries, the HIV epidemic is monophyletic and the rates of drug resistant 
mutations are low (Avi et al., 2014).  
A peak in chronic HCV infections in Estonia occurred during the 1990s – 
preceding the HIV epidemic – remained high at the beginning of 2000s 
(Figure 1 and Figure 2), and then decreased steadily mirroring the HIV infection 
rate (Tefanova et al., 2006). The main population affected by HCV has also 
been PWID. According to genotype data, 1b and 3a are the most prevalent HCV 
genotypes among chronic HCV patients and HIV/HCV positive individuals 
(Kase et al., 2015; Zusinaite et al., 2005).  
 
 
Figure 2. The incidence of chronic HCV and HBV infections in Estonia. The 
incidence per 100 000 persons of chronic HCV is marked in green and chronic HBV in 
blue. The data are reported by the Estonian Health Board 
(www.terviseamet.ee/en/information.html).  
 
The prevalence of HBV infections has followed similar trends as HCV 
infections, peaking during the mid-1990s and thereafter gradually decreasing 
(Figure 1 and Figure 2). The main population affected has also been PWID 
(Tefanova et al., 2006). The nationwide HBV vaccination strategy was imple-
mented in 1999 among teenagers and in 2003 expanded to include newborns; 
however, vaccination coverage among the general population is low (Paat et al., 
2009). Considering HBV genotypes, A and D have been recorded in the 
Estonian population, with genotype D accounting for 86% of total HBV cases 
(Tallo et al., 2004).  
Among HIV positive individuals, rates of HCV and HBV co-infections are 
high, especially among PWID. HCV is the most frequent co-infection among 
HIV positive individuals; depending on the studied group, 54–96% of Estonian 
HIV positive PWID are seropositive for HCV (Soodla et al., 2015; Uusküla et 
al., 2007). Data regarding HBV is more complex, showing that more than 20% 
of needle exchange visiting PWID are HBsAg positive, and 6% of HIV positive 
individuals in the Estonian E-HIV database are HBsAg positive (Soodla et al., 
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2015; Uuskula et al., 2006). Numbers of triple-infected individuals are not 
precisely known, however, previous cross-sectional studies have indicated that 
12–40% of PWID may be triple-infected (Huik et al., 2013; Huik et al., 2010). 
 
 
2.3. Factors influencing susceptibility to HIV 
Some individuals remain HIV negative despite repeated exposure (Horton et al., 
2010). The main exposure routes are through unprotected sexual intercourse, and 
intravenous drug use (previously also blood transfusion, especially among 
hemophiliacs). Based on the frequency of exposure, individuals can be classified 
as heavily exposed seronegative subjects (HESN) or exposed seronegative 
subjects (ESN). However, this classification is not very strict and varies across 
studies. Usually study subjects are classified per the frequency of risk behavior(s), 
mostly the number of times they had unprotected sex with a HIV positive partner 
or shared a syringe. The percentages of individuals remaining HIV-seronegative 
vary from 6% among hemophiliacs, 5–10% among commercial sex workers, 
and up to 85% of individuals in serodiscordant relationships (Fowke et al., 1996; 
Kroner et al., 1994; Peterman et al., 1988; Salkowitz et al., 2001). Resistance 
against HIV has been associated with HIV co-receptor CCR5 genetic poly-
morphisms, its cell surface density on CD4+ T cells (Samson et al., 1996), and 
with multiple other genetic factors, for example CCR5 ligand polymorphisms 
(Liu et al., 1996; Zhao et al., 2004). However, the genetic associations found 
have not explained whole resistance to HIV.  
 
 
2.3.1. HIV pathogenesis and route of infection 
HIV infection can be acquired via parenteral, sexual, or vertical routes. Infection 
risk varies by transmission route, being highest via blood transfer, because this 
route avoids the mucosal barrier (Boily et al., 2009; Msellati et al., 1990). The 
risk of HIV transmission from contaminated blood products is 90–100% 
(Donegan et al., 1990; Msellati et al., 1990). The risk of infection during sexual 
exposure is 1 in 200–2000, and depends on multiple co-factors, such as type of 
intercourse, HIV stage, and male circumcision (Boily et al., 2009; Powers et al., 
2008). 
Of all the routes of infection, no significant differences in the overall course 
of HIV infection have been found. The virus is transmitted via mucosal or 
parenteral routes, and establishes a lymphatic reservoir (Haase, 1999). Depending 
on the route of infection, the first viral targets are CD4+ and dendritic cells in 
blood or mucosa (Ayehunie et al., 1997; Blauvelt et al., 1997; Geijtenbeek et 
al., 2000; Schacker et al., 2001). The virus enters the target cells using a CD4 
receptor and co-receptor, mainly CCR5 or to a lesser extent the CX chemokine 
receptor 4 (CXCR4) (Berger et al., 1999; Hladik et al., 2007; Jakobsen et al., 
2010). Viruses using CCR5 as a co-receptor usually prevail in the early phases 
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of infection, and in some cases are replaced by CXCR4 viruses during the later 
stages of infection (Gorry and Ancuta, 2011). The reasons for co-receptor 
switching are not completely understood, but it has been proposed to be linked 
with a declined fitness of CCR5-using viruses or the presence of CXCR4 on 
more cell types than CCR5 (Coetzer et al., 2008). 
The primary clinical infection results in peak HIV viremia and an initial 
decrease in CD4+ T cells, which rise and plateau after the creation of a virus 
specific immune response (Koup et al., 1994). After the initial acute infection, a 
steady state of clinical latency is reached, and for multiple years little change in 
blood immune factors occur. This latency is dependent on the host’s genetics 
and immune reactions. During this stage there is a slight decrease in CD4+ T 
cells, an increase in HIV viral load, and increased immune activation (Deeks et 
al., 2013). The exact mechanisms of immune activation are unknown, however, 
microbial translocation from the gut and HIV antigen exposition itself have 
been proposed (Brenchley et al., 2006; Lederman et al., 2000). The increase in 
immune activation predicts disease progression (Giorgi et al., 1993; Zangerle et 
al., 1992) and drives CD4+ T cells depletion (Lederman et al., 2000). In addition, 
the cytopathic effects of HIV itself contribute to CD4+ decline. Budding of HIV 
virions disrupts cell membranes and compromises single cells, and HIV causes 
the formation of multinucleated cells using uninfected CD4+ T cells (Alimonti 
et al., 2003; Fauci, 1988; Levy, 1993; Lifson et al., 1986). All these events 
eventually lead to cell death, an increase in HIV viral load, and AIDS.  
 
Figure 3. HIV pathogenesis. The CD4+ T cell count is presented with blue and the 
HIV RNA load with red (modified from Rowland-Jones, 2003).  
 
The aforementioned pathogenic processes can be delayed using antiretroviral 
treatments. After the first antiviral treatment regimens were introduced during 
the 1980s and highly active antiretroviral therapy (HAART) during the 1990s, 
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the number of AIDS-related deaths decreased (Hammer et al., 1997). HAART 
enabled suppression of viral replication below the limit of detection (Opravil et 
al., 2000). The treatment stabilizes CD4+ cell counts and reduces the risk of 
opportunistic infections. The newer HAART regimens, especially those including 
integrase inhibitors, have increased the lifespan of HIV positive individuals 
(Deeks et al., 2013).  
Multiple problems regarding HIV infection and pathogenesis are related to 
co-infections. As mentioned, two of the most important viral co-infections among 
HIV positive PWID are HBV and HCV. In addition to these, cytomegalovirus 
(CMV), GB virus type C (GBVC), human T-lymphotropic virus (HTLV), and 
multiple other viruses affect susceptibility to HIV and or its progression (Brites et 
al., 2009; Ernst et al., 2014; Gudo et al., 2009; Hodowanec et al., 2013; Jõgeda et 
al., 2016). 
 
 
2.3.2. Viral factors influencing susceptibility to HIV 
HIV-1 can be divided into three groups: M (major); O (outlier); and N (non-
M/non-O). The most divergent group M, is further divided into nine subtypes 
(A, B, C, D, F, G, H, J, and K) and recombinant forms. To date, intra-subtype 
differences have not been related to increased/decreased susceptibility to HIV 
and or the disease’s progression. Regarding susceptibility, some HIV inter-
subtype differences have been described, however, the differences mostly 
reflect the socio-economic status of the study groups (Campbell, 2006). 
Differences between subtypes A, C, and D have been found among vertically 
infected subjects, where mothers infected with subtype D were less likely to 
transmit the infection to their children (Renjifo et al., 2001; Renjifo et al., 
2004). Similarly, multiple other studies have shown higher subtype C 
transmission risks compared to non-C (Alcântara et al., 2013; John-Stewart et 
al., 2005). However, these results have not been confirmed by larger 
multinational studies (Kahle et al., 2014). Additional subtype effects have been 
proposed among PWID in Thailand, where subtype E resulted in increased 
transmission compared to subtype B (Hudgens et al., 2002). However, many 
other epidemiologic and host factors could have influenced this difference.  
 
 
2.3.3. Host factors influencing susceptibility to HIV 
There are multiple host factors that influence susceptibility to infections. The 
main host factors can be divided into genetic (single nucleotide polymorphisms, 
and copy number variations) and immunologic factors (e.g. levels of cytokines, 
cytokine balances, chemokine receptor expression, T cell distribution). 
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2.3.3.1. Host genetic factors associated with HIV infection 
Host genetics plays a major role in susceptibility to HIV and progression of the 
disease. A lot of effort has been put into determining the host genes associated 
with resistance to HIV and its progression. The main focus of these studies has 
been on genes encoding HIV co-receptors and their ligands, human leukocyte 
antigen (HLA) encoding genes, and other genes related to immune response 
(Chatterjee, 2010).  
CCR5 and CXCR4 are the main HIV co-receptors and polymorphisms in 
these genes directly affect their gene expression, together with co-receptor cell 
surface expression and thereafter viral entry to target cells (Alkhatib et al., 
1996; Feng et al., 1996). The most well-known polymorphism related to HIV 
host genetics is the CCR5 gene 32 base pair deletion (CCR5 ∆32), which in a 
homozygous state provides complete protection against HIV R5-tropic infection 
(Dean et al., 1996; Samson et al., 1996). The deletion results in a shortened 
version of the receptor molecule, which is not transported to the cell surface and 
therefore the cell lacks the co-receptor necessary for viral entry (Benkirane et al., 
1997). Although individuals carrying the CCR5 ∆32 mutation are resistant to 
CCR5 using viruses (R5 tropic), they are susceptible to CXCR4 using viruses 
(Balotta et al., 1997; Gorry et al., 2002). Data regarding ∆32 heterozygote 
individuals is not conclusive, as differences in HIV susceptibility have been found 
in some study groups.  
In addition to the CCR5 ∆32 mutation, multiple other genetic poly-
morphisms – mainly in chemokine genes, chemokine receptor genes, and HLA 
genes – influence susceptibility to HIV and disease’s progression (Table 1). 
Table 1. Associations between human genetic polymorphisms and HIV infection 
Gene Polymorphism Effect Selected references 
CCR5 ∆32/∆32 Resistance to HIV CCR5 
tropic strains 
(Liu et al., 1996) 
(Samson et al., 1996) 
 ∆32/wt Protective against HIV, 
slower progression to AIDS 
(Zimmerman et al., 1997) 
(Marmor et al., 2001) 
 –2459A Faster progression to AIDS (McDermott et al., 1998) 
CCR2 V64I Protective against HIV, 
slower progression to AIDS 
(Singh et al., 2003) 
(Zapata et al., 2013) 
CCL3L1 Low copy number Protective against HIV (Huik et al., 2010) 
CCL5 –28G Slower progression to AIDS
Faster progression to AIDS 
(Liu et al., 1999) 
(Zhao et al., 2004) 
 –403A Protective against HIV, 
slower progression to AIDS 
(Liu et al., 1999) 
(Zhao et al., 2004) 
 1.1T Slower progression to AIDS (Liu et al., 1999) 
SDF1 801A Slower progression to AIDS (Winkler et al., 1998) 
HLA B*27 Slower progression to AIDS (Gao et al., 2005) 
 B*35 Faster progression to AIDS (Carrington et al., 1999) 
 B*57 Slower progression to AIDS (Altfeld et al., 2003) 
 Cw*04 Faster progression to AIDS (Carrington et al., 1999) 
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Another group of genes regarded as important in HIV transmission and 
progression are the genes that code cytokines, cytokine receptors, and other 
immune response genes. Cytokines alter immune response and have an inhi-
bitory or stimulatory effect on immune reactions (Hogan and Hammer, 2001). 
The role of cytokines in HIV infection is presented in Figure 4.  
 
 
Figure 4. Cytokines influencing HIV infection. The arrows indicate a stimulative and 
the blocked arrows an inhibitory effect on HIV infection. (modified from Hogan and 
Hammer, 2001) 
 
Levels of cytokines are influenced by multiple factors, such as their genetic 
polymorphisms. A list of cytokine related gene polymorphisms related to HIV 
infection is presented in Table 2.  
 
Table 2. Associations between human genetic polymorphisms and HIV infection 
Gene Poly-
morphism 
Effect Study 
population 
Reference 
IL-2 166T Protective against HIV Hispanic (Wang et al., 2004) 
 3896A Protective against HIV ALIVE 
cohort 
(Shrestha et al., 2006) 
(Vlahov et al., 1991) 
IL-4 –590T Protective against HIV REACH 
cohort 
(Wang et al., 2004) 
(Wilson et al., 2001) 
IL-6 174C Trend towards faster 
progression to AIDS 
Indian (Sobti et al., 2010) 
IL-10 –592A Higher risk of acquiring 
HIV, faster progression to 
AIDS 
Multiple (Wang et al., 2004) 
(Shin et al., 2000) 
(Naicker et al., 2012) 
 –1082G Higher risk of acquiring HIV,
faster progression to AIDS 
Multiple (Wang et al., 2004) 
TNFα –238A Slower progression to AIDS Caucasian (Nasi et al., 2013) 
TGFβ –509T Higher plasma viral load Hispanic (Freitas et al., 2015) 
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One important cytokine in the context of HIV is IL-10. It is an immuno-
regulatory cytokine secreted by macrophages, monocytes, and T-helper cells 
(Moore et al., 2001). IL-10 inhibits the synthesis of proinflammatory cytokines 
and antigen presentation (Cassatella et al., 1993; de Waal Malefyt et al., 1991). 
It inhibits the production of multiple interleukins, TNF, and chemokines, 
affecting T cell responses (Andrew et al., 1998; Sozzani et al., 1998). 
The IL-10 gene and promoter area possesses multiple genetic polymorphisms, 
of which –592C/A, –819C/T, and –1082G/A are the most studied (Eskdale and 
Gallagher, 1995; Eskdale et al., 1999; Eskdale et al., 1996; Eskdale et al., 1997; 
Lazarus et al., 1997; Turner et al., 1997). The –592 and –819 polymorphisms 
are in complete linkage disequilibrium and with –1082 form three haplotypes 
(GCC, ACC, and ATA) seen among Caucasian individuals (Edwards-Smith et al., 
1999; Lazarus et al., 2002; Turner et al., 1997). In some populations, additional 
haplotypes (ATC and GTA) are present at low frequencies (Ramaseri Sunder et 
al., 2012). These three polymorphisms have been associated with susceptibility 
to HIV and its progression to AIDS (Oleksyk et al., 2009; Shin et al., 2000; 
Wang et al., 2004). Multiple studies have shown that –592A increases suscepti-
bility to HIV infection and predisposes individuals to a faster progression to 
AIDS (Chatterjee et al., 2009; Naicker et al., 2012; Naicker et al., 2009; 
Oleksyk et al., 2009; Wang et al., 2004). –1082G carriers are more likely to 
acquire a HIV infection than –1082A carriers (Sun et al., 2013; Wang et al., 
2004). Both polymorphisms have been associated with IL-10 production: –
592A has been associated with low and –1082G with high IL-10 expression 
(Crawley et al., 1999; Edwards-Smith et al., 1999; Larsson et al., 2010; Reuss et 
al., 2002). However, the effects of these two polymorphisms in terms of 
susceptibility to HIV requires further investigation, because the effects of IL-10 
production levels as a consequence of these two alleles seem to be opposite.  
 
2.3.3.2. T cell factors associated with susceptibility to HIV infection 
In addition to genetic factors, susceptibility to HIV is influenced by host immuno-
logical factors, including T cell distribution and cell surface marker expression. 
Among HIV positive individuals, alterations in T cell subtypes and cell surface 
marker expressions have been described. These changes include loss of CD4+ T 
cells, an increase in immune activation, and alterations in multiple other immune 
functions. Similar changes, such as decline in CD4+ and an increase in immune 
activation, have been described among multiple cohorts of HIV exposed sero-
negative individuals (ESN) (Biasin et al., 2000; Killian et al., 2004; Suy et al., 
2007; Tran et al., 2006; Yang et al., 2002). Two hypotheses regarding changes 
in the immune system of ESN have been proposed: (a) these changes are a 
consequence of HIV exposure; or (b) they are constitutive characteristics of an 
individual that result in low susceptibility to HIV (Suy et al., 2007). 
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2.3.3.2.1. T lymphocyte classification 
All human blood cells, including T lymphocytes, are derived from hematopoietic 
stem cells (Figure 5). Multiple classifications based on cell surface marker 
expression have been used to describe T lymphocytes. CD3+ cells are divided 
into CD4+ and CD8+ T cells, and thereafter both cell types are categorized into 
naïve and memory cell subsets. An additional group of CD4+ T cells are T 
regulatory cells (Treg), which express CD4, FOXP3, and CD25. 
 
 
Figure 5. Blood cell development. All blood cells derive from multipotential hemato-
poietic stem cells and through multiple stages of differentiation CD3+ T lymphocytes 
are formed. T cells are further divided into CD4+ T helper cells and CD8+ cytotoxic T 
cells, and then into naïve and memory cells. 
 
Multiple classification methods have been used to divide CD4+ and CD8+ T 
cells into memory subtypes. Two widely used classifications are based on 
expression of CD45RA and CD45RO or CD45RA and CCR7 on cell surface. 
The simpler classification divides the cells using CD45RA and CD45RO into 
naïve (CD45RA+) and memory cells (CD45RO+). During transition from naïve 
to memory cells, there also exists a fraction of double positive CD45RA+RO+ 
cells, however, whether this cell type possesses distinct functions is unknown 
(Hamann et al., 1996). 
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The second classification divides T cells into four groups based on the 
expression of CD45RA and CCR7: naïve (TN; CD45RA+ CCR7+); central 
memory (TCM; CD45RA– CCR7+); effector memory (TEM; CD45RA– CCR7–); 
terminally differentiated (TTEMRA; CD45RA+ CCR7–) (Mahnke et al., 2013). 
When simply modelled, these cell types have a progenitor–product relationship 
(Figure 6) and distinct immunological functions. After antigen exposition, T 
cells evolve into TCM cells and thereafter TEM cells with immediate effector 
functions (Hamann et al., 1997; Sallusto et al., 1999). The final step in differen-
tiation are TTEMRA cells, which have low functional and reproductive capabilities 
(Geginat et al., 2003). 
In addition to markers that divide cells into memory subtypes, T cells express 
immune activation markers such as CD38 and HLA-DR, and viral co-receptors 
such as CXCR4 and CCR5. These immune activation markers are mostly 
expressed on memory cells and HIV-specific T cells (Douek et al., 2002; Mahnke 
et al., 2013; Meditz et al., 2011). Both HIV co-receptors CCR5 and CXCR4 are 
expressed on T cells, however, CCR5 is mainly expressed on activated/memory 
cells and CXCR4 on naïve cells (Bleul et al., 1997; de Roda Husman et al., 
1999). Therefore, CCR5-tropic HIV strains mainly infect memory CD4+ T cells 
(Schnittman et al., 1990); however, some CCR5+ memory cells, for example 
some types of TTEMRA, can be resistant to HIV infection (Oswald-Richter et al., 
2007). 
 
 
 
Figure 6. T cell differentiation. TN = naïve; TCM = central memory; TEM = effector 
memory; TTEMRA = terminally differentiated cells. Each cell type has different cell 
surface markers and produces different soluble substances (modified from Farber et al., 
2014). 
 
2.3.3.2.2. Changes in T cell populations and cell surface  
marker expression during exposure to and infection by HIV 
Changes in all the aforementioned T cell populations are eminent among HIV 
positive individuals. These individuals have decreased numbers of CD4+ T cells 
and an increased percentage of CD8+ memory cell types. For example, HIV 
positive individuals have increased TEM cell types and a T cell distribution 
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skewed towards terminally differentiated cells compared to healthy controls 
(Appay et al., 2002; Serrano-Villar et al., 2014). However, a higher proportion 
of TTEMRA cells is protective against HIV progressing to AIDS (Northfield et al., 
2007; Oswald-Richter et al., 2007). An important cell type in controlling HIV 
infections is Treg , which reduce chronic immune activation, but conversely, can 
decrease direct anti-viral responses (Munier et al., 2013). As Treg cells express 
the HIV co-receptor CCR5, they are possible targets for HIV infection (Schulze 
Zur Wiesch et al., 2011). The role and dynamics of this cell type during HIV 
infection is not yet clear, however, their levels can both increase and decrease 
during the persistent infection stage (Schulze Zur Wiesch et al., 2011; 
Simonetta et al., 2012).  
Similar trends have been noticed among ESN, whereas their immune system 
changes in similar directions to HIV positive individuals, however, these 
alterations can depend on the route and level – for example their partner’s viral 
load – of exposure (Biasin et al., 2000; Camara et al., 2010; Hasselrot et al., 
2010; Jennes et al., 2003; Lo Caputo et al., 2003; Restrepo et al., 2010; Suy et 
al., 2007; Tran et al., 2006). Multiple studies have shown that ESN have skewed 
levels of CD4+/CD8+ T cells and or memory cell subpopulations, and in most 
cases increased levels of effector cells (Biasin et al., 2000; Jennes et al., 2003; 
Lo Caputo et al., 2003; Restrepo et al., 2010; Suy et al., 2007). These findings 
are summarized in Table 3. In addition to T cell distribution changes, both HIV 
positive individuals and ESN have altered expression of immune activation 
markers and HIV co-receptors. During HIV progression, the level of cells 
expressing immune activation markers increases (Meditz et al., 2011; Tiba et 
al., 2011).  
The third T cell property extensively studied among sexually exposed 
subjects is the expression of the HIV co-receptor CCR5, and to a lesser extent 
CXCR4. As mentioned, CCR5 expression is dependent on multiple genetic and 
epigenetic polymorphisms in the CCR5 promoter region (Gornalusse et al., 
2015; Thomas et al., 2006). However, during HIV infection CCR5 levels 
increase and correlate with a faster progression to AIDS (Bleul et al., 1997; 
Ostrowski et al., 1998; Yang et al., 2012). CCR5 levels also correlate with 
immune activation, because CCR5 is mainly expressed on activated cells 
(Meditz et al., 2011; Pierson et al., 2000). The situation among ESN is not as 
clear. Depending on the study population, CCR5 increased/decreased on CD4+ 
and or CD8+ T cells. For example, Tran et al. (2006) have shown decreased 
CCR5 expression among PWID, however, Suy et al. (2007) showed increased 
CCR5 expression among heterosexually exposed individuals. Regarding 
CXCR4, similarly contradictory results have been published showing both 
increased and decreased receptor expression during HIV infection (Jennes et al., 
2003; Messele et al., 2001).  
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Table 3. Differences in T cell populations of HIV exposed seronegative individual 
(ESN) compared to controls 
T cell subset Direction Route of exposure References 
CD4+ ↓ Heterosexual (Lo Caputo et al., 2003) 
(Suy et al., 2007) 
CD4+CD45RA+ ↑ 
 
↓ 
Heterosexual (Jennes et al., 2003) 
(Lo Caputo et al., 2003) 
(Suy et al., 2007) 
(Biasin et al., 2000) 
CD4+CD45RA+RO+ ↑ Heterosexual (Suy et al., 2007) 
CD45RO+ ↑ Heterosexual (Biasin et al., 2000) 
CD4+HLA-DR+ ↑ Heterosexual (Suy et al., 2007) 
CD4+CD38+ ↑ Heterosexual (Suy et al., 2007) 
(Tran et al., 2006) 
CD4+CCR5+ ↑ Heterosexual 
Parenteral 
(Suy et al., 2007) 
(Truong et al., 2003) 
CD4+CXCR4+ ↓ Heterosexual 
Parenteral 
(Jennes et al., 2003) 
(Tran et al., 2006) 
CD8+ ↑ Heterosexual 
Parenteral 
Homosexual 
(Killian et al., 2004) 
(Lo Caputo et al., 2003) 
(Tran et al., 2006) 
(Yang et al., 2002) 
CD8+CD28+ ↓ Heterosexual 
Parenteral 
(Suy et al., 2007) 
(Tran et al., 2006) 
CD8+HLA-DR+ ↑ Heterosexual (Suy et al., 2007) 
CD8+CD38+ ↑ Heterosexual (Biasin et al., 2000) 
(Suy et al., 2007) 
(Tran et al., 2006) 
CD8+CCR5+ ↓ Parenteral (Tran et al., 2006) 
CD8+CXCR4+ ↓ Parenteral (Tran et al., 2006) 
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2.4. Factors influencing susceptibility and  
progression of HBV and HCV 
HIV, HBV, and HCV share routes of infection and co-infections are common. 
However, compared to HIV, both HBV and HCV can cause acute infections 
leading to chronic illness. The factors influencing hepatitis susceptibility and 
progression to chronic illness depend on both viral and host factors. 
 
 
2.4.1. HBV and HCV pathogenesis 
HBV infection occurs via multiple routes, for example from contaminated blood 
products, intravenous drug use (IVDU), mother-to-child transmission (MTCT), 
or unprotected sexual intercourse, especially among MSM (Remis et al., 2016). 
During acute infection, hepatocytes are mainly infected (Seeger and Mason, 
2015; Summers et al., 2003). In 90% of adults, acute infections are resolved with 
the help of multiple cytokines, such as IFNα and IFNγ, and a vigorous CD4 and 
CD8 response (Ferrari et al., 1990; Liaw and Chu, 2009; Lucifora et al., 2014; 
Rehermann et al., 1995; Wieland et al., 2004). During chronic infection, HBV 
replication and accumulation of HBV viral proteins can lead to liver injury 
(Bertoletti et al., 2003; Chisari, 1997; Pugh and Summers, 1989). The reasons 
for chronic infection might be related to inhibition of antibody and T cell 
response by viral proteins, and the size of viral inoculum (Asabe et al., 2009; 
Chen et al., 2004; Chisari et al., 2010).  
HCV is transmitted mainly through parenteral exposure (contaminated blood 
products or IVDU), and to a lesser extent MTCT (MacDonald et al., 2000). 
Similar to HIV, some HCV-exposed individuals remain uninfected, however, 
the mechanisms of this protection are unknown (Thurairajah et al., 2008; 
Warshow et al., 2012). An adequate CD8+ T cell response is thought to be the 
key factor in self-limiting infection. In the absence of an adequate cytotoxic T 
lymphocyte (CTL) response, acute HCV develops into a chronic infection 
(Chang et al., 2001; Grüner et al., 2000; Thimme et al., 2001).  
 
 
2.4.2. Host factors associated with HBV and HCV infections 
Similar to HIV, host factors influence susceptibility to hepatitis and its progres-
sion. Host factors can be divided into genetic and immunological. These host 
factors can in turn be divided into factors associated with acute and or chronic 
hepatitis infection. 
 
2.4.2.1. Host genetic factors associated with HBV and HCV infections 
Multiple studies have focused on the influence of genetic factors upon the course 
chronic HBV and HCV infections. Less attention has been paid to the influence 
of polymorphisms upon susceptibility to hepatitis or spontaneous clearance. As 
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T cell function is crucial in clearing HBV, genetic factors that determine immune 
responses to viruses have received the most attention (Table 4). For example, 
multiple polymorphisms in JAK/STAT pathway genes have been associated 
with chronic hepatitis B (Lu et al., 2015; Zhu et al., 2005).  
 
Table 4. Associations between human genetic polymorphisms and HBV infection 
Gene Poly-
morphism 
Effect Study 
population 
Selected references 
IL-6 –572G Associated with HBV 
spontaneous 
clearance 
Chinese (Lu et al., 2014) 
IL-10 –592A Associated with HBV 
persistence 
Associated with 
asymptomatic HBV 
Multiple (Cheong et al., 2006) 
(Peng et al., 2006) 
(Ahmadabadi et al., 
2012) 
IL-18 –607A  
 
 
–137G 
Associated with HBV 
seronegativity 
Associated with HBV 
seronegativity 
 (Karra et al., 2015) 
IL-20 1807T Decreased risk of 
chronic HBV 
Caucasian (Truelove et al., 
2008) 
BIM rs3827537A Elevated risk of 
chronic HBV  
Han Chinese (Peng et al., 2015) 
TNFγ –238A Decreased 
susceptibility to HBV
Han Chinese (Wang et al., 2012) 
IFNγ 874A Associated with 
intrauterine HBV 
Chinese (Zhu et al., 2005) 
STAT4 rs7574865T, 
rs7282694C, 
rs11889341T, 
rs8179673C 
Decreased risk of 
chronic HBV 
Han Chinese (Lu et al., 2015) 
 
Host genetic factors play a major role in HCV pathogenesis, viral clearance, and 
treatment outcome. Studies among multiple ethnic populations have highlighted 
the role of interleukin genes in terms of susceptibility and spontaneous 
clearance (Table 5). For example, studies of IL-10 have shown that –592A and 
–1082C are associated with an increased risk of chronic HCV (Edwards-Smith 
et al., 1999; Knapp et al., 2003; Mangia et al., 2004; Sun et al., 2013). Additional 
genetic polymorphisms that affect the outcome of HCV infection are listed in 
Table 5. Most of the studies were focused on HCV viral clearance or treatment 
outcome; fewer studies have been conducted regarding susceptibility to HCV. 
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Table 5. Associations between human genetic polymorphisms and HCV infection 
Gene Poly-
morphism 
Effect Study 
population 
Selected references 
IL-2 –330T Higher risk of chronic 
HCV and or HBV 
Han 
Chinese 
(Gao et al., 2009) 
IL-4 
 
33C Decreased risk of 
chronic infection  
Brazilian (Ramos et al., 2012) 
IL-10 –592A Higher HCV 
spontaneous clearance 
Multiple (Sun et al., 2013) 
(Mangia et al., 2004) 
(Edwards-Smith et 
al., 1999) 
 –1082G Increased/decreased risk 
of chronic infection  
HIV+/HCV
+ Caucasian 
Brazilian 
(Sun et al., 2013) 
(Persico et al., 2006) 
(Ramos et al., 2012) 
IL28B rs 12979860C 
rs 8099917T 
Decreased risk of 
chronic infection 
Brazilian (Ramos et al., 2012) 
(Kurbanov et al., 
2011) 
TNFα –238G Increased risk of liver 
cirrhosis 
Caucasian (Corchado et al., 
2013) 
IFNγ 874A Higher risk of chronic 
HCV  
Han 
Chinese 
(Gao et al., 2009) 
 rs2069707G Asociated with 
spontaneous clearance of 
HCV 
 (Azam et al., 2015) 
TLR9 rs187084C Associated with 
spontaneous clearance in 
women 
Swiss (Fischer et al., 2016) 
 
2.4.2.2. T cell factors associated with HBV and HCV infections 
Multiple studies investigating chronic HBV and HCV infections have been 
conducted, however, studies investigating factors related to hepatitis sero-
positivity are lacking. In both self-limiting and chronic infections, CD4+ and 
CD8+ cell response determines the course of infection (Grakoui et al., 2003; 
Schmidt et al., 2013). A lack of adequate T cell response correlates with chronic 
infection (Ferrari et al., 1990; Grakoui et al., 2003; Rehermann et al., 1995; 
Thimme et al., 2001). 
At the beginning of acute HBV infection, T-helper 1 response, together with 
IFNγ production, is triggered (Wieland et al., 2004). Thereafter, a HBV-specific 
CD8+ response is responsible for virus eradication (Thimme et al., 2003). 
During the acute infection phase, the level of TCM cells increases, which is 
replaced by an increase in TEM cells during the chronic infection phase 
(Carotenuto et al., 2011; Sobao et al., 2002).  
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During the acute HCV infection phase, CD8+CD38+ T cell response, together 
with IFNγ and CD4+ responses, determine the outcome of the infection. A lack 
of adequate T cell response results in chronic HCV (Thimme et al., 2001). 
These HCV-specific T cells responses are detectable – in the liver, where the 
cells mostly reside, not in peripheral blood – decades after the initial infection 
and help clear re-infections (He et al., 1999; Osburn et al., 2010; Takaki et al., 
2000). One important aspect of HCV clearance is the ability to produce IFNγ to 
suppress viral replication (Gruener et al., 2001; Jo et al., 2009). However, high 
levels of immunosuppressive IL-10 are associated with progression to chronic 
infection (Flynn et al., 2011). During HCV infection, high numbers of HCV-
specific TEM and TTEMRA cells are produced, and immune activation occurs 
(Appay et al., 2002; Shen et al., 2010; Urbani et al., 2002).  
 
 
2.5. IVDU and its relationship to T cell distribution and  
HIV, HBV, and HCV susceptibility 
According to the United Nations Office of Drugs and Crime (UNODC), about 1 
in 20 adults worldwide used at least one drug in 2014, and over 29 million 
people have drug use disorders (UNODC, 2016). There were approximately 12 
million intravenous drug users in 2013, all of whom have an elevated risk of 
death due to overdose or HIV infection (Mathers et al., 2013). Worldwide, 
about 14% of PWID are HIV positive (EMCDDA, 2015; UNODC, 2016). The 
overall trend in the EU indicates that IVDU account for about 8% of new HIV 
cases, however, the level is up to 22 times higher in the Baltic region 
(EMCDDA, 2015; UNAIDS, 2014). In addition to HIV, PWID are also exposed 
to HCV and HBV (Estrada, 2002; Rahimi-Movaghar et al., 2010; Zhou et al., 
2012). In the EU, HCV antibody prevalence among PWID ranges from 14–84% 
and worldwide, about 6 million PWID are anti-HBc positive (EMCDDA, 2015; 
Nelson et al., 2011). 
The effects of drug use on the immune system depend on the substance and 
dose consumed (Peterson et al., 2004). Experiments regarding opioids have 
mainly been conducted on animal models or cell cultures; in vivo data are limited. 
Most studies have focused on morphine, which inhibits IL-2 transcription and 
increases IL-4 and IL-12 production, which directs T cells into the T-helper 2 
lineage (Börner et al., 2009; Messmer et al., 2006; Roy et al., 2004; Sacerdote et 
al., 2003; Wang et al., 2003). Through the suppression of IFNα and IFNγ, 
morphine decreases CD8+ T cell responses (Wang et al., 2005). In addition, 
morphine up-regulates HIV co-receptor CCR5 expression, increasing the risk of 
HIV infection (Mahajan et al., 2005). Similar effects with CCR5 increase or T 
cell permissiveness to HIV infections have been noted with cocaine, heroin, and 
methadone (Baum et al., 2009; Friedman et al., 2003; Kim et al., 2013; Li et al., 
2002; Steele et al., 2003; Suzuki et al., 2002). 
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2.6. Summary of the literature 
Some individuals remain HIV-uninfected despite repeated exposure. Most of 
the studies investigating these individuals have focused on men having sex with 
men, serodiscordant couples, and commercial sex workers (Horton et al., 2010). 
Data regarding persons who inject drugs remains limited. 
Most studies have focused on genetic polymorphisms and their effect upon 
susceptibility to HIV and its progression. In addition to the HIV co-receptor 
CCR5, researchers have focused on the HLA region and the effect of interleukin 
polymorphisms on viral susceptibility. For example, two polymorphisms in the 
IL-10 promoter region (–1082 and –592) have been associated with suscept-
ibility to HIV and its disease progression. However, the results of these studies 
have depended on the study groups involved; information about persons who 
inject drugs remains limited. 
In addition to genetic polymorphisms, immunological responses to HIV 
infection have been investigated. Multiple studies have shown that HIV exposed 
seronegative individuals have an altered T cell distribution (increased numbers 
of memory T cells), higher levels of immune activation, and differences in CCR5 
expression, compared to healthy volunteers. As with genetic studies, analysis 
has focused mainly on sexually exposed subjects. However, the defense mecha-
nisms against HIV might be different during parenteral exposure, because in 
this case there is no mucosal barrier.  
When investigating PWID populations, other blood borne infections, such as 
HBV and HCV, must be taken into account. Both genetic and immunological 
factors influence HBV and HCV clearance and the course of chronic infections. 
The main focus of studies has been on the course of infections, not sus-
ceptibility, because it is more difficult to recruit groups to assess the factors that 
affect susceptibility or hepatitis spontaneous clearance.  
The Estonian PWID population consists mainly of young male Caucasian 
individuals infected with monophyletic HIV-1 CRF06_cpx viruses (Adojaan et 
al., 2005; Avi et al., 2011; Avi et al., 2010). This provides an opportunity to 
analyze the effects of genetic polymorphisms upon susceptibility to HIV among 
a homogenous population, without taking into account the potential effects of 
ethnic and viral variation. There are high rates of opioid use, especially 
fentanyl, among Estonian PWID (Uusküla et al., 2007; Uusküla et al., 2015b). 
Similar to other PWID populations, Estonian PWID are often co-infected with 
HIV, HBV, and or HCV viruses, making it possible to analyze the effects of co-
infections on immunological factors (Soodla et al., 2015; Uusküla et al., 2007). 
In conclusion, genetic polymorphisms, immunological factors, and IVDU 
play an important role in HIV, HBV, and HCV infections. This thesis focuses 
on two IL-10 polymorphisms (–1082C/A and –592G/A) and T cell distribution 
in the seropositivity of HIV, HBV, and HCV infections and their co-infections 
among persons who inject drugs. 
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3. AIMS OF THE STUDY 
The general aim of this thesis was to assess the effect of IL-10 polymorphisms 
on susceptibility to HIV, HBV, and or HCV, and to determine how exposure 
and seropositivity to these viruses influences T cell distribution among a 
Caucasian PWID population.  
 
The study had the following specific objectives: 
 
1. To investigate whether and how the IL-10 genetic polymorphisms –1082 and 
–592 affect susceptibility to HIV, HBV, and or HCV infections in PWID 
2. To examine the associations between HIV exposure, CCR5 expression, 
immune activation (the number of HLA-DR+ cells) and T cell distribution 
among PWID 
3. To investigate the associations between HIV co-infections (HIV/HCV or 
HIV/HBV or HIV/HBV/HCV) and CCR5 expression, immune activation, 
and T cell distribution among PWID 
4. To investigate whether and how intravenous drug use influences CCR5 
expression, immune activation, and T cell distribution among PWID 
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All three studies were conducted in Caucasian PWID (formerly regarded as 
intravenous drug users – IDU) recruited in 2011 Tallinn, Estonia. A total of 345 
subjects were enrolled from syringe exchange program using respondent-driven 
sampling (Malekinejad et al., 2008) by the Estonian National Institute for 
Health Development and the Institute of Family Medicine and Public Health of 
University of Tartu. Venous blood samples and interviewer administered ques-
tionnaire was obtained from all study subjects. The questionnaire included 
questions regarding demographical data such as date of birth, gender, nationality, 
duration of IVDU, and other risk behaviors. Of all the PWID (Figure 7), 173 
were HIV negative. From these HIV negative individuals, 20 reported syringe/ 
needle sharing at least once a month during the six months prior to the interview. 
They were assigned as heavily exposed HIV seronegative subjects (HESN). In 
addition, 47 HIV negative PWID reported syringe/needle sharing at least once 
within the previous six months and they were classified as exposed HIV 
seronegative subjects (ESN). Similar categorization for HBV and HCV was used. 
From the 345 PWID, 13 highly exposed subjects were HBV and 4 HCV negative.  
 
 
 
Figure 7. The classification of persons who inject drugs (PWID). HESN – heavily 
exposed HIV seronegative subjects, ESN – exposed seronegative subjects. 
 
The main characteristics of the studies are presented in Table 6. The studies 
included two different control groups. The first group consisted of 496 blood 
donors collected in Tallinn and Ida-Viru County in 2010. The demographic data 
of these controls was not available. The second control group consisted of 47 
HIV, HBV, HCV negative healthy volunteers matched by age- and sex to the 
ESN group. They were recruited in 2012–2013 in Tartu, Estonia. 
To determine, the associations between frequent HIV exposure, HESN were 
selected as the study group in IL-10 study. Because these individuals are rare 
and difficult to recruit, a bigger sample size of ESN was chosen for the flow 
cytometry studies, to increase the power of the study. 
4. MATERIALS AND METHODS 
4.1. Study design and population 
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Table 6. Studies that form basis of this thesis 
Study 
name 
Study populations Primary aim Publi-
cation 
IL-10 
study 
PWID (n = 345) 
 HIV+ (n = 172) 
 HIV– (n = 173) 
 HESN (n = 20) 
Blood donors (n = 496) 
To determine the associations between 
IL-10 –1082 and –592 polymorphisms 
and HIV, HBV, and HCV seropositivity 
1 
T cell 
HIV 
study 
PWID (n = 88) 
 HIV+ (n = 41) 
 ESN (n = 47) 
Controls (n = 47) 
To determine the associations between 
HIV seropositivity, CCR5 expression, 
immune activation, and T cell 
distribution 
2 
T cell co-
infection 
study 
To determine the associations between 
HIV, HBV and HCV co-infections, 
IVDU CCR5 expression, immune 
activation, and T cell distribution 
3 
Note: PWID – persons who inject drugs, HESN – heavily exposed HIV seronegative subjects, 
ESN – exposed seronegative subjects 
 
 
4.2. Ethical considerations  
All studies were approved by the Research Ethics Committee of the University 
of Tartu (Ethics Review Committee approval no 204/T-13 in 08.06.2011, 209T-
16 in 11.12.2011, and 216/T-18 in 25.06.2012). All subjects signed informed 
consent and blood donors agreed with using leftover blood for research. 
 
 
4.3. Sample collection and processing 
For IL-10 polymorphisms analyses, leftover samples of blood donors were 
collected into EDTA tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and 
stored at +4 °C. After HIV, HCV and HBV testing, confirmed seronegative 
blood samples were sent to the laboratory of University of Tartu, Department of 
Microbiology. The blood samples were stored at –80 °C for DNA extraction. 
From each PWID and flow cytometry control subject, 16 ml venous blood was 
collected into EDTA tubes (VACUETTE®, Greiner Bio-One GmbH, Fricken-
hausen, Germany) and transported to the laboratory of the University of Tartu, 
Department of Microbiology within 24 hours. Thereafter, peripheral blood 
mononuclear cells (PBMC) were separated using Ficoll gradient and stored at –
80 °C in freezing media (90% fetal bovine serum and 10% dimethyl sulfoxide).  
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4.4. HIV, HBV and HCV antibody testing 
The serostatus testing for HIV was performed in the Estonian Central HIV 
Reference Laboratory using a fourth generation enzyme-linked immunoassay 
(Vironistica HIV Uniform II Ag/Ab, BioMerieux, Marcy Etoile, France) as 
previously described by Huik et al. (Huik et al., 2013). The results were con-
firmed by using immunoblotting (INNO LIA HIV I/II Score Westernblot, 
Microgen Bioproducts Ltd, Surrey, UK). The HBV and HCV serostatuses were 
defined in the laboratory of the Estonian National Institute for Health Develop-
ment. The HBV antibodies and antigens were detected with ETI-MAK-4 
HBsAg and ETI-AB-COREK Plus (both DiaSorin, Saluggia, Italy). Vaccination 
status against HBV was defined based on the HBs Ab. The seropositivity of 
HCV was tested with the ETI-AB-HCVK-3 test (DiaSorin, Vercelli, Italy). 
 
 
4.5. Determination of IL-10 promoter polymorphisms 
For the detection of IL-10 promoter polymorphisms, genomic DNA was 
extracted from blood donors’ whole blood samples and PBMC samples of 
PWID using PureLink® Genomic DNA Kit (Invitrogen, Applied Biosystems 
Foster City, CA, USA) according to the manufacturer’s instructions and there-
after stored at – 80 °C. IL-10 polymorphisms –1082G/A and –592C/A (rs1800896 
and rs1800872, respectively) were analyzed using 7900HT Fast Real-Time PCR 
System and TaqMan allelic discrimination assays (both Applied Biosystems 
Foster City, CA, USA) (De La Vega et al., 2002). 
 
 
4.6. T cell distribution analysis 
The T cell subsets, immune activation (HLA-DR expression), and CCR5 expres-
sion were determined using multi-color flow cytometry. The thawed PBMC were 
diluted using 1x Dulbecco’s phosphate-buffered saline (DPBS, Sigma Life Science, 
St. Louis, MO, USA) and stained with titrated fluorochrome-conjugated mo-
noclonal antibodies (Table 7) according to antibody’s manufacturer’s instructions.  
 
Table 7. Monoclonal antibodies used for the experiments 
Cell surface marker Fluorochrome Manufacturer 
CD3 PerCP-Cy5.5 Biolegend, San Diego, CA, USA 
CD4 FITC Biolegend, San Diego, CA, USA 
CD8 PE Biolegend, San Diego, CA, USA 
CD45RA PE-Cy7 Biolegend, San Diego, CA, USA 
CD45RO BV711 Biolegend, San Diego, CA, USA 
CCR7 (CD197) PE-CF594 Biolegend, San Diego, CA, USA 
HLA-DR BV510 Biolegend, San Diego, CA, USA 
CCR5 (CD195) APC Becton Dickinson, Franklin Lakes, NJ, USA 
32 
Thereafter cells were fixed with 1x FACS lysing solution (Becton Dickinson, 
Franklin Lakes, NJ, USA) and washed twice with 1x DPBS (Sigma Life 
Science, St. Louis, MO, USA). Next, cells were dissolved in 500 µl of 1% 
formaldehyde (Sigma-Aldrich, St. Louis, MO, USA) and analyzed within two 
hours on a LSR Fortessa flow cytometer (Becton Dickinson, Franklin Lakes, 
NJ, USA). The flow cytometer configuration is presented in Table 8. For the 
flow cytometry data analyses FACS Diva software version 6.2 (Becton 
Dickinson, Franklin Lakes, NJ, USA), automatic compensation calculations, and 
fluorescence minus one (FMO) controls for CCR5 and HLA-DR were used. All 
data analyses were performed in a blinded manner. The data are presented as 
percentages from the parent cell populations. Additionally to percentages, the 
CCR5 cell surface density was analyzed as median fluorescence intensities 
(MFI-s). 
For the HIV susceptibility study, the T cells were hierarchically divided into 
CD4+ and CD8+ T cells and thereafter in to naïve (CD45RA+CD45RO–) and 
memory cells (CD45RA–CD45RO+). For the co-infection study, a more complex 
allocation of memory cells was used. Both CD4+ and CD8+ T cells were 
divided into naïve (TN; CD45RA+ CCR7+), central memory (TCM; CD45RA– 
CCR7+), effector memory (TEM; CD45RA– CCR7–), and terminally differen-
tiated (TTEMRA; CD45RA+ CCR7–) cells based on CD45RA and CCR7 expres-
sion. In addition, in both studies the percentages of activated cells (HLA-DR+) 
and CCR5+ cells were measured. To avoid spectral overlap in the CCR5 
analyses, the CCR5-APC was the only fluorochrome chosen for the red laser. 
 
Table 8. LSR Fortessa configuration 
Laser Wavelength Mirror Filter Parameter 
Violet 405 670 LP 710/40 BP BV711 
  505 LP 525/50 BP BV510 
Blue 488 685 LP 710/50 BP PerCP-Cy5.5 
  505 LP 530/30 BP FITC 
  – 488/10 BP SSC 
Yellow-Green 561 750 LP 780/60 BP PE-Cy7 
  600 LP 610/20 BP PE-CF594 
  – 586/15 BP PE 
Red 640 – 670/14 BP APC 
Note: SSC – side scatter, LP – longpass, BP – bandpass 
 
 
 
 
 
33 
4.7. CCR5 Δ32 analyses 
To analyze the effect of CCR5 Δ32 mutation on the CCR5 expression, DNA 
was extracted from PBMC samples of flow cytometry study subjects (47 
controls, 41 ART naïve HIV positive PWID, and 47 ESN) using PureLink® 
Genomic DNA Kit (Invitrogen, Foster City, CA, USA). The CCR5 Δ32 was 
analyzed using PCR at the laboratory of the University of Tartu, Department of 
Microbiology as described previously by Samson et al. (Samson et al., 1996).  
 
 
4.8. Statistical analysis 
In all studies R version 2.13 was used for statistical analyses and p-values 
< 0.05 were considered statistically significant. The p-values in IL-10 analyses 
were not corrected for multiple testing. 
Fisher's exact test was used for the IL-10 polymorphism allele frequencies 
and genotype pairs’ analyses. Uni- and multivariate logistic regression was used 
for determining the associations between IL-10 polymorphisms and HIV and 
HBV serostatuses. Two different models were used for the comparisons: allele 
and genotype model. In both models the allele/genotype of interest was 
compared to the sum of all other alleles/genotypes. In addition, Hardy-Wein-
berg Equilibrium was tested in all alleles (Rodriguez et al., 2009).  
The differences in the T cell subset analyses were determined using Mann-
Whitney-Wilcoxon test and the frequency of CCR5 Δ32 mutation with Fisher’s 
exact test. Holm–Bonferroni method was used for adjusting the results for 
multiple comparisons. 
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5. RESULTS AND DISCUSSION 
5.1. The effect of IL-10 polymorphisms on HIV, HBV,  
and HCV serostatus (Paper I) 
Paper I describes the influence of IL-10 polymorphisms in positions –592 and –
1082 on the HIV, HBV, and HCV serostatus of Caucasian PWID. This is the 
first study to evaluate IL-10 –1082 and –592 alleles, genotypes, and genotype 
pairs among Eastern-European Caucasian PWID. 
 
 
5.1.1. Population characteristics in the IL-10 study 
Detailed characteristics of the study population are summarized in Table 9. The 
median duration of IVDU was 11 years, and the PWID subjects had high 
percentages of HCV and HBV infections (89% and 67%, respectively). Demo-
graphical and HBV vaccination data of the blood donors was not available. 
 
Table 9. Characteristics of the PWID 
 PWID (n = 345) 
Males, n (%) 272 (79%) 
Age in years, median (IQR) 30 (25–34) 
Duration of IVDU (years), median (IQR) 11 (7–14) 
HIV seropositive, n (%) 172 (50%) 
HCV seropositive, n (%) 306 (89%) 
HBV seropositive, n (%) 232 (67%) 
HBV vaccinated, n (%) 43 (12%) 
Note: IQR = interquartile range 
 
 
5.1.2. IL-10 allelic frequencies and HIV serostatus 
The allelic frequencies of IL-10 –1082 and –592 among the study groups are 
presented in Table 10. The –1082A allele and the –592C allele were the most 
frequent in all groups (Table 10).  
 
Table 10. Allelic frequencies in study populations 
 –1082 –592 
 A G C A 
PWID (n = 345) 0.57 0.43 0.78 0.22 
   HIV negative PWID (n = 173) 0.55 0.45 0.76 0.24 
     HESN (n = 20) 0.70 0.30 0.70 0.30 
   HIV positive PWID (n = 172) 0.59 0.41 0.80 0.20 
Blood donors (n = 496) 0.54 0.46 0.79 0.21 
Note: PWID = persons who inject drugs, HESN = heavily exposed HIV seronegative subjects 
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Regarding HIV infection, differences in both –1082 and –592 polymorphisms 
were observed between HESN and blood donors. The allelic frequencies of  
IL-10 –1082 and –592 were similar between PWID and blood donors. However, 
all HESN had at least one –1082A allele compared to 81.4% of HIV positive 
PWID (p=0.029) and 79.0% of blood donors (p=0.019). 
When investigating position –592, HESN had more A carriers than HIV 
positive PWID (60% and 34.3%, p=0.029). In univariate analyses, –592A was 
associated with decreased odds of HIV infection (OR 0.35; 95% CI 0.13–0.90; 
p=0.029), which remained significant after adjustment to HCV, HBV serostatus, 
and IVDU (OR 0.28; 95% CI 0.10–0.81; p=0.019).  
To sum up, IL-10 promoter polymorphisms –1082A and –592A were over-
represented among HESN compared to HIV positive PWID. 
Multiple studies have analyzed the effects of IL-10 polymorphisms –1082 
and –592 on susceptibility to HIV and its progression. However, studies among 
PWID have been limited and they have not been analyzed separately, but in 
pools with sexually exposed individuals (Shin et al., 2000; Wang et al., 2004). 
More data is available about the –592C/A polymorphism in relation to suscepti-
bility to HIV, where the –592A has been associated with increased suscepti-
bility to HIV among multiple cohorts of different ethnicities and exposure routes 
(Chatterjee et al., 2009; Naicker et al., 2009; Shin et al., 2000; Shrestha et al., 
2006). These results are opposite to those of the current study; only a small 
study has observed a higher –592A frequency among HIV/tuberculosis co-
infected patients compared to controls (Ramaseri Sunder et al., 2012). The 
reasons for this discrepancy with larger studies are unknown, but might be 
related to the type of study subjects. Most studies have investigated mixed ethnic 
and exposure groups, neither focusing solely on Caucasian nor parenterally 
exposed subjects (Chatterjee, 2010; Naicker et al., 2009; Shin et al., 2000; 
Wang et al., 2004). In addition, none of these studies analyzed individuals with 
high expose to HIV, which could account for the differences between this and 
previous studies. Another reason for dissimilarities might be other poly-
morphisms of the IL-10 gene and promoter region, or combinations of different 
interleukin gene polymorphisms (for example IL-10 together with IL-6) not 
detected during this study that may have affected IL-10 production and inter-
leukin balance, and therefore susceptibility to HIV (Eskdale et al., 1999; Eskdale 
et al., 1996; Eskdale et al., 1997; Gibson et al., 2001; Sobti et al., 2010). Less data 
are available about –1082A/G polymorphism, however, similarly to the results of 
the current study, –1082G has been associated with susceptibility to HIV among 
multiple study cohorts (Ramaseri Sunder et al., 2012; Wang et al., 2004).  
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5.1.3. IL-10 genotype frequencies and HIV serostatus 
Next, the distribution of IL-10 genotypes was assessed (Table 11). As 
mentioned in the previous chapter, all HESN possessed at least one –1082A 
allele and therefore no –1082GG homozygotes were found, compared to 18.6% 
of HIV positive PWID and 21.0% of blood donors (p=0.029 and p=0.019, 
respectively). In addition, HESN had less –592CC homozygotes than HIV 
positive PWID (40.0% and 65.8%, respectively; p=0.029). 
 
Table 11. Genotype frequencies among the different study populations, n (%) 
 –1082 –592 
 AA AG GG CC AC AA 
PWID (n = 345) 117 (34) 159 (46) 69 (20) 212 (61) 114 (33) 19 (6) 
HIV– PWID (n =173) 55 (32) 81 (47) 37 (21) 99 (57) 65 (38) 9 (5) 
HESN (n = 20) 8 (40) 12 (60) 0 (0) 8 (40) 12 (60) 0 (0) 
HIV+ PWID (n = 172) 62 (36) 78 (45) 32 (19) 113 (66) 49 (28) 10 (6) 
Blood donors (n = 496) 141 (28) 251 (51) 104 (21) 306 (62) 167 (34) 23 (5) 
 
Figure 8 shows, that the percentage of –592AC heterozygotes was higher 
among HESN than HIV positive PWID and blood donors (60.0% to 28.3% and 
60.0% to 33.7%; p=0.009 and p=0.028, respectively). Persons possessing –
592AC had decreased odds of HIV infection compared to those not carrying this 
genotype (OR 0.27; 95% CI 0.10–0.69; p=0.064). It remained significant after 
adjusting for HCV and HBV serostatus, and IVDU (OR 0.24 95% CI 0.08–
0.69; p=0.008).  
 
 
Figure 8. The frequency of the IL-10 –592AC genotype compared to HIV serostatus 
among heavily exposed HIV seronegative individuals (HESN), HIV positive persons 
who inject drugs (HIV+ PWID), and blood donors. Blue indicates those with and violet 
those without the genotype. Values in the columns represent the numbers and percen-
tages of subjects carrying the genotype. 
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Although the –592A and –592A allele containing genotypes have been associated 
with increased susceptibility to HIV, opposite to the results of the current study, 
data regarding the heterozygote genotype is largely absent (Naicker et al., 2009; 
Shin et al., 2000). Only a small-scale study conducted among Indian 
HIV/tuberculosis patients has shown high –592AC genotype frequency among 
HIV positive individuals (Ramaseri Sunder et al., 2012). Based on these two 
studies, one might hypothesize that in addition to the –592A allele having a 
protective effect, the –592AC heterozygote genotype that is over-represented 
among HESN is protective against HIV. However, as the –592AA genotype 
was rare among the study groups (5–6% of subjects), and the HESN study group 
was very small, the potential protective effect of just –592A alleles against HIV 
infection cannot be excluded. 
 
 
5.1.4. IL-10 genotype pair frequencies and HIV serostatus 
Among the study subjects, six genotype pairs comprising of –1082 and –592 
genotypes were present (Figure 9). Among all populations, the most common 
genotype pair was AG/CC (–1082/–592).  
 
 
Figure 9. The frequency of IL-10 genotype pairs among persons who inject drugs 
(PWID), HIV negative PWID, heavily exposed HIV seronegative individuals 
(HESN), HIV positive PWID, and blood donors. Pink indicates those with AA/AA, 
grey those with AG/AC, yellow those with AA/AC, green those with GG/CC, blue 
those with AG/CC, and violet those with AA/CC genotype pairs. Values in the columns 
represent the number of subjects. 
 
The HIV positive PWID group had less individuals with AG/AC genotype pairs 
compared to blood donors (12.8% and 20.2%, respectively; p=0.03) (Figure 
10a). As all HESN lacked the –1082GG genotype, no one had a GG/CC geno-
type pair (Figure 10b). In addition, the HESN group had more individuals with 
the AA/AC genotype pair than the blood donor group (30.0% and 13.5% 
respectively; p=0.049) (Figure 10c). 
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Figure 10. The frequency of IL-10 genotype pairs AG/AC, GG/CC, and AA/AC 
compared to HIV serostatus among heavily exposed HIV seronegative individuals 
(HESN), HIV positive persons who inject drugs (HIV+PWID), and blood donors. 
Blue indicates those with and violet those without the respective genotype pair among 
the HESN, HIV positive PWID, and blood donor groups. Values in the columns 
represent the number and percentage of subjects carrying the given allele. 
 
Overall, HESN had overrepresentation of AG/AC and AA/AC genotype pairs, 
and underrepresentation of GG/CC genotype pairs, compared to controls. 
At least 50% of IL-10 production is genetically determined and both –592A 
and –1082A have been associated with low IL-10 expression (Crawley et al., 
1999; Reuss et al., 2002; Westendorp et al., 1997). Therefore, haplotypes com-
prised of –1082A and –592A have the lowest IL-10 expression and –1082G and 
–592C the highest (Crawley et al., 1999). Based on the current study, 
possessing a low IL-10 producing genetic variant is protective against HIV. 
Comparing the results of the current with previous studies, some differences are 
apparent, as the –592A allele has mainly been associated with increased sus-
ceptibility to HIV (Naicker et al., 2009; Shin et al., 2000; Wang et al., 2004). 
39 
These differences could be explained by the analyzing of additional poly-
morphisms in the IL-10 promoter region during other studies. Wang et al. 
(2004) investigated the presence of multiple IL-10 polymorphisms in large HIV 
study cohorts and found that –1082G is protective against HIV and –592A 
increases susceptibility to HIV. However, when the same study analyzed IL-10 
haplotypes comprised of 5 SNPs in the region, the results were somewhat 
opposite to the allele frequency results. More specifically, –1082G/–592C con-
taining genetic variants were associated with increased and –1082A/–592A with 
decreased susceptibility to HIV, which is in accordance with the results of the 
current study. Overall, this shows that not only alleles, but their combinations, 
must be taken into account when analyzing IL-10 polymorphisms, and that low 
IL-10 producing genetic variants are protective against HIV. 
The protective effect of low IL-10 producing variants against HIV might be 
related to CCR5 expression. Multiple studies have shown that IL-10 up-regulates 
HIV co-receptor CCR5 expression and promotes HIV infection (Alfano and 
Poli, 2005; Juffermans et al., 2000; Sozzani et al., 1998; Wang et al., 2002). In 
addition, an IL-10 deficiency enhances HIV viral clearance and functional T-
cell response (Brooks et al., 2006). Based on these mechanisms, lower IL-10 
producing genetic variants could be protective against HIV.  
 
 
5.1.5. IL-10 polymorphisms and HCV and HBV serostatus 
The allelic frequencies between HBV-seropositive and -seronegative PWID and 
HCV-seropositive and -seronegative PWID were similar. Only one significant 
difference was observed with HCV: HCV negative PWID were less likely to 
have a AG/CC genotype pair than blood donors (15.4% and 30.4%, respec-
tively; p=0.046). 
Of the HBV negative PWID, 13 were highly exposed to the virus – reported 
syringe/needle sharing at least once a month during the previous six months and 
were not vaccinated against HBV – yet seronegative. Similar to the HIV results, 
highly exposed HBV seronegative PWID had more –592AC heterozygotes than 
HBV positive PWID (61.5% and 33.7%, respectively; p=0.03) (Figure 11a). 
Presence of –592AC was associated with decreased odds of HBV infection 
(OR 0.28; 95% CI 0.09–0.87; p=0.028), which remained significant after 
adjustment for HCV and HIV serostatus, and the duration of intravenous drug 
use (OR 0.29; 95% CI 0.09–1.00; p=0.05). Due to the increased number of –
592AC among HBV exposed seronegative PWID, they also had more AG/AC 
genotype pairs than HBV positive PWID and blood donors (46.2% to 14.2% 
and 46.2% to 20.2%; p=0.008 and p=0.034, respectively) (Figure 11b). Persons 
not carrying AG/AC had approximately five times lower odds of being HBV 
positive compared to AG/AC carriers (OR 0.19; 95% CI 0.06–0.61; p=0.052); 
this remained significant in multivariate analyses (OR 0.20; 95% CI 0.06–0.70; 
p=0.012).  
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Figure 11. IL-10 –592AC and the genotype pair AG/AC among HBV seronegative 
exposed persons who inject drugs (PWID), HBV positive PWID, and blood donors. 
Blue bars indicate those with and violet bars without the given genotype (panel a) or 
genotype pair (panel b). Values in the columns represent the number and percentages of 
subjects. 
 
Multiple studies have evaluated the effect of IL-10 genetic polymorphisms in 
the context of HBV spontaneous clearance or treatment outcome. There are no 
studies that have investigated IL-10 polymorphisms and HBV susceptibility 
among PWID. Owing to the different outcomes of studies (HBV clearance or 
treatment outcome) and variable study populations (ethnicity, exposure route, 
and co-infections), results have been inconclusive, demonstrating both positive 
and negative effects of –592A during chronic HBV infection (Cheong et al., 
2006; Gao et al., 2009; Miyazoe et al., 2002; Peng et al., 2006). Some 
researchers have hypothesized that higher IL-10 levels might decrease effective 
immune responses against HBV infection, leading to chronic or occult HBV 
infection, and that the carriers of –592A do not clear the virus spontaneously 
(Ramezani et al., 2012; Shin et al., 2003; Truelove et al., 2008). The results of 
the current study imply that similar to HIV infection and HBV progression, high 
IL-10 producing genetic variants appear to have higher susceptibility to HBV. 
However, based only on the results of the current study, it is not possible to 
draw generalized conclusions regarding the role of IL-10 polymorphisms in 
susceptibility to HBV, thus additional studies of larger populations are needed 
to clarify the effects of IL-10. 
 
 
5.2. T cell distribution and CCR5 expression in PWID  
(Papers II and III) 
Papers II and III describe the differences in T cell distribution and CCR5 
expression among multiple groups of PWID and controls. PWID were cate-
gorized based on their HIV status and then according to the presence or absence 
of HBV and or HCV co-infections. 
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5.2.1. Population characteristics in the T cell study 
The characteristics of the study population are presented in Table 12. In terms 
of age and gender, PWID and controls were similar. Less PWID were vaccinated 
against HBV than controls (13% and 49%, respectively; p<0.001). 
 
Table 12. Characteristics of the study population 
 PWID (n = 88) Controls (n = 47) 
Gender Male, n (%) 72 (82%) 39 (83%) 
Age Years, median (IQR) 30 (25–33) 29 (25–33) 
Duration of intravenous drug use Years, 
median (IQR) 11 (7–14) NA 
Receptive syringe sharing During last six 
months, n (%) 83 (94%) NA 
HBV vaccination n (%) 11 (13%) 23 (49%) 
Note: PWID = persons who inject drugs; controls = unexposed seronegative subjects; IQR = 
interquartile range. 
 
The PWID population was characterized by high levels of co-infections. In 
total, half of PWID were HIV positive, most of them HCV positive, and 55 
(63%) HBV seropositive (Figure 12). Of PWID, 35 (40%) had a triple infection 
(HIV+ HBV+HCV+) and only 11 (8%) were seronegative of all three viruses. 
 
 
Figure 12. HIV, HCV, and HBV serostatus among the PWID. The white circle re-
presents all PWID, the blue circle HCV+ PWID, the green circle HBV+ PWID, the red 
circle HIV+ PWID, and the overlapping areas co-infected subjects. HCV serostatus was 
based on HCV Ab+ and HBV serostatus on anti-HBc or HBsAg+. 
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The 135 study subjects were divided into three groups: (a) 41 HIV positive 
PWID; (b) 47 HIV exposed seronegative PWID (ESN); (c) 47 controls matched 
to the ESN by gender and age.  
 
 
5.2.2. T cell distribution in relation to HIV susceptibility 
One subject’s flow cytometry data analyses is presented on Figure 13. The used 
flow cytometry panel gives a good overview of the whole CD4+ and CD8+ T 
cell distribution among the study subjects, because of the use of eight colors 
simultaneously enabling the allocation of the cells into many subtypes. In 
addition, the CCR5 APC is the only fluorochrome in the red spectral area 
enabling exact measurements of HIV co-receptor CCR5 signal. 
The main results of the T cell analyses in relation to HIV serostatus are pre-
sented in Table 13. HIV positive individuals showed typical changes in their cell 
percentages. As expected, HIV positive PWID had lower percentages of CD4+ 
T cells and more immune activation (higher percentages of HLA-DR+ cells) 
compared to ESN. In addition, HIV-positive PWID showed increased per-
centages of both CD4+CD45RA+RO+ and CD8+CD45RA+RO+ double-positive 
cells compared to ESN. 
When comparing the two HIV negative groups (ESN and controls), three main 
differences were observed. First, ESN had higher percentages of CD4+ and CD8+ 
CD45RA+CD45RO+ cells compared to controls (0.8% to 0.5% and 0.8% to 
0.3%, respectively; p=0.016 in both cases). Similar trends have been described 
by Suy et al. (2007) among sexually exposed individuals. Thus, an increase in 
double positive cells occurs among sexually and parenterally exposed individuals, 
and being similar in two exposure routes is rather caused by HIV-exposure and 
not intravenous drug use. The role of these double positive cells during infec-
tions, including HIV, is unknown, however, their number increases during various 
infections, including HIV disease progression (de Roda Husman et al., 1999; 
Palacios-Martínez et al., 2012; Rentenaar et al., 2000). Therefore, these cells 
might just reflect an overall T cell response during HIV exposure and or 
infection, or possess a specific function in susceptibility to HIV and its progres-
sion not yet fully understood. 
The second main difference between ESN and controls was the higher 
percentage of immune activated cells among ESN (Table 13). ESN had higher 
percentages of HLA-DR+ cells of all the studied CD4+ and CD8+ T cell 
subtypes (CD45RA+, CD45RA+RO+, and CD45RO+) compared to controls. 
These results are similar to those of previous studies among sexually exposed 
individuals, where higher immune activation, likely caused by extensive viral 
exposure, has been demonstrated (Biasin et al., 2000; Lo Caputo et al., 2003; 
Restrepo et al., 2010; Suy et al., 2007). Only a few studies have investigated the 
effects of HIV exposure among PWID ESN (Makedonas et al., 2002; Tran et al., 
2006).  
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5.2.3. CCR5 expression in relation to susceptibility to HIV 
The third major aspect analyzed during the T cell study, was the number of 
CCR5+ cells and expression of CCR5. Prior to CCR5 flow cytometry analysis, 
CCR5 32 base-pair deletion (Δ32) was examined to assess its effects on CCR5 
expression. The proportion of Δ32 heterozygotes was 17% in ESN, 27% in HIV 
positive PWID, and 15% in controls. The percentages were not significantly 
different between the three groups (ESN to HIV+ PWID p=0.331; HIV+PWID 
to controls p=0.193, and ESN to controls p=0.785). The percentages of Δ32 
heterozygotes were in similar ranges to those of previous studies in Estonia 
(Adojaan et al., 2007). In addition, one ESN was homozygous of the mutation 
and had no CCR5 expression of T cells, which verified the flow cytometry data. 
Excluding individuals with at least one Δ32 mutation (Δ32/wt and Δ32/ Δ32) 
did not change the results of comparisons between ESN and controls of T cell 
subset analyses. As seen in Figure 14, the CCR5 wild type homozygotes had 
higher percentages of CCR5+ cells and higher CCR5 MFI values compared to 
carriers of one Δ32 allele (wt/Δ32 heterozygote), indicating lower CCR5 
expression among CCR5 heterozygote individuals.  
 
 
Figure 14. The ratio (median %) of CCR5+ lymphocyte subsets from the parent 
cell population (a and b), CCR5 median fluorescent intensities (MFIs; c and d), 
and interquartile ranges of all study subjects. White represents wt/wt homozygotes 
and grey wt/Δ32 heterozygotes.
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These studies also found higher immune activation among ESN compared to 
controls. Overall, with regard to the current and previous studies (Biasin et al., 
2000; Jennes et al., 2003; Restrepo et al., 2010; Suy et al., 2007), one can 
conclude that immune activation in exposed individuals occurs and that the 
mechanism of immune activation among ESN is independent of the route of 
infection. The effect of immune activation on susceptibility to HIV in not fully 
understood. Although HIV exposure increases the expression of CCR5 and 
therefore the number of cells susceptible to HIV, an effective immune response 
together with immune activation is necessary for prevention of HIV infection 
(Makedonas et al., 2002; Ostrowski et al., 1998; Restrepo et al., 2010).  
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HIV positive PWID had higher percentages of CD4+CD45RA+RO+CCR5+ cells 
than ESN and controls (5.7% to 10.3% and 5.7 to 13.3%; p=0.028 and p=0.015, 
respectively) and higher percentages of CD8+CD45RA+RO+CCR5+ cells than 
controls (20.0% to 30.0%; p=0.006) (Table 13). In terms of CCR5 expression 
level (MFI), ESN had lower CCR5 surface density of CD4+CCR5+ and 
CD8+CCR5+ cells (Figure 15) than HIV positive PWID. CCR5 expression did 
not differ between the HIV positive and HIV negative PWID groups, regardless 
of their HIV serostatus.  
These results were somewhat surprising, showing that CCR5 expression on 
CD4+ T cells was higher among controls than HIV negative and HIV positive 
PWID. These results contrast with previous studies, which have showed increased 
percentages of CCR5 expression during exposure to HIV (half of the PWID 
population was ESN) and in vitro opioid exposure (Li et al., 2002; Steele et al., 
2003; Suy et al., 2007). Multiple opioids, such as methadone and morphine, in-
crease the expression of CCR5 via the μ-opioid receptor (Li et al., 2002; Steele 
et al., 2003). Similarly to the current study, Tran et al (2006) showed decreased 
percentages of CD8+CCR5+ cells among Vietnamese PWID. The higher and 
lower CCR5 expression reported in the literature could be explained by genetic 
polymorphisms other than Δ32 deletion in the CCR5 gene and promoter region, 
epigenetic modifications, or by multiple other factors such as co-infections (de 
Roda Husman et al., 1999; Gornalusse et al., 2015). However, the CCR5 expres-
sion similarities between PWID groups suggests that CCR5 expression may be 
related to IVDU, regardless of HIV serostatus. 
 
 
Figure 15. CCR5 median fluorescent intensities (MFIs) and interquartile ranges of 
CCR5+ cell numbers of the study groups. Blue indicates HIV exposed seronegative 
subjects (ESN), pink indicates HIV positive persons who inject drugs (PWID), and 
green indicates controls (unexposed seronegative subjects). Panel (a) indicates total 
CD4+ CCR5+ and (b) total CD8+ CCR5+ cells. 
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5.2.4. T cell distribution in relation to HIV, HCV,  
and HBV seropositivity 
Multiple studies have analyzed the effects of HIV, HBV, and HCV mono-infec-
tions on T cell distribution, however, data regarding co-infections, especially 
among PWID, is limited. To analyze the effect of HIV, HCV, and HBV co-
infections, flow cytometry study subjects were divided into five groups:  
 
 Group (a) HIV+HCV+HBV+ PWID (n = 35);  
Group (b) HBV+HCV+ dual positive PWID (n = 18);  
Group (c) HIV–HBV–HCV+ PWID (n = 17); 
Group (d) Triple negative PWID (n = 11); 
Group (e) Controls (n = 47). 
 
Multiple T cell subsets differed between HIV+HBV+HCV+ PWID and HIV 
negative PWID (HIV–HBV+HCV+, HIV–HBV–HCV+, and triple negative). In 
addition to lower percentages of CD4+ T cells and higher percentages of CD8+ 
T cells from the parent cell population, HIV+ individuals had lower percentages 
of CD4+ TCM and higher percentages of CD4+ TTEMRA cells than HIV negative 
but HBV+HCV+ PWID (Figure 16b, c). In addition, HIV+HBV+HCV+ PWID 
had lower percentages of CD8+ TN and CD8+ TCM, and higher percentages of 
CD8+TEM cells, than other PWID groups (Figure 16). HIV+HBV+HCV+ had 
higher percentages of HLA-DR+ cells compared to HIV–HBV+HCV+ PWID 
and HIV–HBV–HCV+ PWID (Figure 17). In terms of CCR5, triple infected 
PWID had higher levels of CD8+ TN CCR5+ and CD8+ TCM CCR5+ cells than 
PWID with HBV/HCV dual- or HCV mono-infection (Figure 18a–c). Overall, 
most of the observed differences were between HIV positive and HIV negative 
PWID groups. 
Although this study did not analyze HIV mono-infected subjects, but co-in-
fected subjects, the results are similar to those found among HIV mono-infected 
individuals (Killian et al., 2004; Suy et al., 2007; Yang et al., 2002). The changes 
among HIV infected individuals included a decrease in percentages of CD4+ T 
cells, an increase in percentages of memory cell subpopulations, and an increase 
in immune activation. These results indicate that T cells distribution changes 
among HIV+HBV+HCV+ (triple infected) PWID are driven by HIV infection, 
whereas seropositivity of hepatitis infections has minimal or no additional 
effects on T cell distribution. 
Analyzing only HIV negative subjects, we found T cell distribution did not 
differ between HBV+ HCV+ dual-infected to HCV mono-infected patients and 
triple negative PWID to HCV mono-infected PWID (Table 14). HBV+ HCV+ 
co-infected PWID had lower percentages of bulk CD4+ T cells than triple 
negative PWID (52.1% and 58.6%, respectively; p=0.021; Figure 16a). Previous 
studies have shown that both HIV exposure and hepatitis infections may lead to 
CD4+ cell decline (Asabe et al., 2009; Grakoui et al., 2003; Yang et al., 2002).  
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However, during hepatitis infections, the majority of changes are localized in the 
liver and not observable in peripheral blood (Appay et al., 2002; He et al., 1999; 
Urbani et al., 2002). Thus, we speculate that the mild decrease in total CD4+ T 
cell populations among HIV negative HBV+/HCV+ PWID may have been caused 
by either HBV/HCV seropositivity and or exposure to HIV. 
Multiple studies have investigated the effect of HIV/HBV or HIV/HCV co-
infections on T cell distribution (Gras et al., 2015; Hodowanec et al., 2013; Kottilil 
et al., 2009; Kovacs et al., 2008; Rallón et al., 2011; Restrepo et al., 2010). The 
current study is the first to evaluate the effects of all three infections in a PWID 
population. Current study showed that independent of their co-infection status, 
PWID who have HIV exhibited the typical changes associated with HIV infection 
(CD4+ cell decline and increased immune activation). HBV/HCV co-infected PWID 
also had a mild decrease in CD4+ T cells compared to triple negative PWID.  
A similar decrease in CD4+ T cells during HBV and HCV mono-infections 
has been demonstrated in primate studies and during fibrosis, but has not been 
studied in PWID populations (Asabe et al., 2009; Grakoui et al., 2003; Rashkin et 
al., 2010). As one might assume that HBV/HCV co-infected PWID are more 
frequently exposed to HIV than seronegative subjects, the reason for CD4+ 
decline might be associated with exposure to HIV or intravenous drug use per se. 
It is interesting to note that the CCR5 analysis results differed somewhat between 
the two flow cytometry studies. In the first study, the percentages of CCR5 positive 
cells were similar between ESN and controls, but ESN had lower CCR5 MFI on 
multiple T cell subsets compared to controls. In the second study, triple negative 
PWID had increased percentages of CCR5+ cells compared to controls. In the first 
study, differences were seen in CCR MFI levels and in the second analysis in 
CCR5 percentages. We can only speculate what caused these differences; co-
infections (absent in triple negative PWID) or some additional factors among ESN 
not yet known might have been responsible. Consequently, percentages of CCR5 
cells and CCR5 expression levels are interesting topics for further research. 
 
 
5.2.5. T cell distribution and intravenous drug use 
To evaluate how IVDU affects the immune system, we compared triple negative 
PWID to controls. All the PWID had a history of syringe/needle sharing and there-
fore potential exposure to infections. The results can be seen in Paper III Supple-
mentary Table 2 and Figure 19. Of the memory cell subsets, two differed bet-
ween triple negative PWID and controls. First, triple negative PWID showed 
lower percentages of CD4+ TEM cells and higher percentages of CD8+ TCM cells 
compared to controls (Figure 19a and Figure 19g). Additionally, triple negative 
PWID had higher percentages of immune activated cells and CCR5+ cells 
compared to controls (Figure 19b–f, h–k). 
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To the best of our knowledge, this is the first study to investigate T cell distri-
bution, immune activation, and the number of CCR5+ cells among triple negative 
PWID. The results complement earlier in vitro and animal studies, which showed 
that opioids increase immune activation and CCR5 expression (Bayer et al., 
1990; Steele et al., 2003; Wang et al., 2007; Wang et al., 2011). In addition, higher 
percentages of CD8+ TCM cells and lower percentages of CD4+ TEM cells among 
triple negative PWID compared to controls indicate that the immune system is 
already compromised by IVDU, despite individuals remaining seronegative of 
HIV, HBV, and HCV. 
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6. GENERAL DISCUSSION 
HIV, HBV, and HCV share routes of infection and factors that influence an 
individual’s susceptibility to them. Despite numerous studies investigating genetic 
and immunological aspects of these three infections, studies among PWID have 
so far been limited. The current study is the first to evaluate associations between 
(a) IL-10 gene polymorphisms, HIV and HCV infections, and T cell distribution 
and (b) HIV, HBV, and HCV infections, among Caucasian PWID. 
 
 
6.1. The importance of conducting studies among PWID 
HIV, HBV, and HCV are among the most influential infections globally and the 
problem among PWID is especially serious, among whom co-infections are 
common. In most regions of the world, hetero- and homo-sexual routes of infec-
tion are the most frequent, and studies among these groups have been abundant. 
However, in Eastern-Europe, IVDU is one of the leading causes of new HIV 
infections and PWID represent an important study group (DeHovitz et al., 2014; 
Kroner et al., 1994; Soodla et al., 2015). Most fascinating are PWID who are 
exposed to the viruses yet remain seronegative. Knowing the factors distinguishing 
ESN from the general population makes it possible to reveal new insights 
regarding the factors that protect some individuals from viruses and thereby 
develop vaccines or drugs against these infections. 
Sexual and parenteral exposure are somewhat different, for example because 
of the different first cell populations affected during HIV exposure (Levy, 2007). 
During sexual exposure, Langerhans and dendritic cells are the first to encounter 
HIV, whereas during parenteral exposure, CD4+ blood cells are the first (Hu et 
al., 2000; Koppensteiner et al., 2012). As mentioned, sexually exposed individuals 
have been studied more than PWID, because (1) it is the most frequent exposure 
route and (2) these individuals are relatively easy to recruit. In contrast, numbers 
of PWID are relatively smaller and various legal and socio-economic issues 
make their enrollment into studies – especially into long-term or cohort studies – 
much more challenging. This thesis is important owing to the analysis of PWID, 
which has provided new insights into the mechanisms that affect susceptibility to 
HIV during parenteral exposure.  
One important characteristic of PWID populations are the HIV/HCV/HBV 
triple or HIV/hepatitis dual infection individuals that are rare among sexually 
exposed populations (Uuskula et al., 2006). Co-infections increase immune 
activation, cause cell exhaustion, and increase viral susceptibility and afterwards 
quicken disease progression (Gudo et al., 2009; Markowitz et al., 2016). There-
fore, it was possible to investigate the effects of various infections on each other’s 
susceptibility and progression. 
The second important characteristic of infections among PWID is the homo-
genous nature of the virus transmitted, which enables the evaluation of human 
genetic factors and T cell distribution, without taking into account additional 
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viral factors (Adojaan et al., 2005; Avi et al., 2014). Among sexually exposed 
populations, the viruses are much more diverse, making it hard to differentiate bet-
ween genetic and immunological reactions of the host and viral strain differences.  
 
 
6.2. Study design 
The most important factor of this study was the study population. As mentioned, 
PWID subjects are hard to recruit and therefore studies among PWID are 
limited. Especially important were the ESN and HESN study groups, which 
revealed new factors that protect against HIV. The study was cross-sectional and 
the T cell distribution and HIV, HBV, and HCV seropositivity in PWID blood 
samples was evaluated only at one time-point, thus giving an overview of the 
study subjects’ immune status at just one time-point, as past/future infections are 
not possible to assess. This was important in both the IL-10 polymorphism and T 
cell analyses, because the study subjects could seroconvert and as the HESN and 
ESN study groups were small, the seroconversion of a few individuals could 
significantly have changed the study results. 
In the IL-10 study, the frequency of two polymorphisms (–592 and –1082) 
were detected, giving the opportunity to analyze IL-10 genotype pairs. The 
detection of two main polymorphisms influencing IL-10 protein production, 
provided a good overview of how IL-10 effects susceptibility to HIV and HBV. 
As the number of HCV highly exposed seronegative subjects was very low (only 
four individuals), larger studies involving highly exposed individuals should be 
conducted to evaluate the effects of IL-10 polymorphisms on HCV sero-
positivity. In addition, during this study the stage of hepatitis infections was not 
assessed, and the role of IL-10 polymorphisms on HBV and HCV disease 
progression among PWID was not clarified.  
One of the main strengths of the study is the 8-colour flow cytometry analyses 
of samples. It enabled the simultaneous evaluation of multiple immunological 
markers, without having to color the samples of the same patients multiple times, 
which might have created bias amongst the analyses. In addition, it was possible 
to analyze multiple CCR5+ and HLA-DR+ memory cell subpopulations. Studies 
involving so many markers in the same flow cytometry analyses have not been 
carried out among similar PWID populations. Such flow cytometry panels are 
complicated to design due to spectral overlap. Although some study groups have 
investigated T cell differences among PWID, they have not used as many markers 
or have pooled the PWID with sexually exposed/infected subjects (Tran et al., 
2006; Truong et al., 2003). 
In this study, two classifications of memory T cell subsets were used: an older 
CD45RA/CD45RO expression based division; and a newer CD45RA/CCR7 based 
classification (Mahnke et al., 2013). The simplified CD45RA/RO classification 
enabled us to confirm the results of HIV exposure studies conducted among 
sexually exposed populations and among PWID, to study the percentages of 
CD45A+RO+ double positive cells (Biasin et al., 2000; Killian et al., 2004; Suy 
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et al., 2007), and to analyze the CCR5 expression during simplified memory cell 
division. The analyses of both the number and surface density of CCR5 cells 
provided a comprehensive overview of this marker’s expression, whereas in 
most studies only the percentage of cells or MFI has been used (Suy et al., 2007; 
Tran et al., 2006; Yang et al., 2012). In the co-infection study, the use of the 
newer memory cells classification gave a more comprehensive overview of the 
topic  
 
6.3. Study limitations 
The main limitation was the cross-sectional nature of the sample collection, 
whereby T cell distribution could be influenced by extreme values at the specific 
time-point. It was not possible to analyze T cell distribution over a longer time 
period to evaluate median values, thus changes in immunological markers (such 
as percentages of CD4+ or CD8+ cell proportions) remained unknown. In 
addition, the risk-behavior (syringe sharing) of the study subjects was based only 
on self-reporting. This may have resulted in an underestimation of the study 
subjects’ risk behavior and should not have produced false positive results when 
analyzing the effect of drug exposure or HIV exposure to T cell distribution.  
As mentioned, differentiation between hepatitis disease stages was not 
possible during this study. Disease stage (acute, chronic, and self-limiting) is 
especially important in HCV studies, where re-infection is common among 
PWID (Osburn et al., 2010). Both HBV and HCV cause acute and chronic 
infections. As during these infections different types of memory cells are increased 
(TCM or TEM), it makes the stage of hepatitis important to assess (Appay et al., 
2002; Carotenuto et al., 2011; Urbani et al., 2005; Urbani et al., 2002). Unfor-
tunately, a lack of clinical data did not allow us to evaluate the course of infection 
or distinguish between chronic and acute hepatitis infections, or HIV disease stage. 
Nonetheless, this cross-sectional study enabled the evaluation of the factors that 
affect the susceptibility to infections of PWID with high cost-effectiveness.  
The detection of differences between genetic polymorphisms and the studied 
infections, may be limited owing to the small number of exposed seronegative 
subjects. The recruitment of PWID was based on calculations of previous similar 
cross-sectional studies conducted among PWID in Tallinn; unfortunately is was 
not possible to recruit more triple negative subjects as they are very rare among 
this population (Uusküla et al., 2015a). Therefore, the power of IL-10 study was 
low. This lack of exposed seronegative subjects would mainly cause false negative 
results, together with an underestimation of the effect on polymorphisms on the 
studied infections. The study could be used in future meta-analyses combining 
different studies, and advanced by analyzing similar polymorphisms in larger 
sample sizes, especially with regard to HCV.  
In flow cytometry analyses, the levels of cell surface markers could be 
influenced by the freezing of PBMC samples, for example CCR5 expression 
decreases during storage (Shalekoff and Tiemessen, 2001). Analysis of whole 
blood was not available, therefore the absolute numbers of T cells and T cell 
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subsets were not measured. The data are presented in the current thesis as 
subpopulation percentages of the parent population. The multicolor flow cyto-
metry panel might have caused false positive results due to spectral overlap, 
however, FMO controls and a strict gating strategy were used to reduce this 
problem. Regardless of these limitations, the results are thought to accurately 
describe the studied parameters among PWID. 
 
 
6.4. The influence of IL-10 polymorphisms on susceptibility 
to HIV, HBV, and HCV infections 
One of the main genes of interest in HIV studies is the virus’s co-receptor CCR5 
Δ32 mutation, which is protective against HIV (Samson et al., 1996). A lot of 
effort is being put into finding new genes that could have a similar protective 
effect. One of the possibilities for finding candidate gene variants are genome 
wide association studies (GWAS). These have revealed multiple genetic variants 
that might be protective against HIV (Joubert et al., 2010; Limou et al., 2012; 
Lingappa et al., 2011). However, GWAS studies overlook genes with smaller 
effects on susceptibility to HIV, but these can be found during monogenetic 
studies. During these monogenetic studies, multiple immune response gene 
variants, such as IL-10 single nucleotide polymorphisms, have been associated 
with protection against HIV. IL-10 is responsible for the balance between 
immunosuppression and inflammation, making it an interesting study subject 
during persistent viral infections. As 50–70% of IL-10 production levels are 
genetically determined, single nucleotide polymorphisms can affect suscepti-
bility to viral infections via the regulation of interleukin production (Reuss et al., 
2002; Westendorp et al., 1997). Part of this regulation is caused by the transcrip-
tion factor Sp1 binding to only IL-10 –1082G alleles, increasing IL-10 production. 
In addition, IL-10 increases CCR5 expression on T cells during HIV infection 
and inhibits virus specific T cell responses (Alfano and Poli, 2005; Brockman et 
al., 2009; de Waal Malefyt et al., 1991; Juffermans et al., 2000; Larsson et al., 
2010; Sozzani et al., 1998; Wang et al., 2002). IL-10 levels increase during 
persistent viral infections and high IL-10 producing genotypes might increase 
susceptibility to other infections seen among PWID (Barcellini et al., 1995; 
Ejrnaes et al., 2006; Talaat et al., 2014). The level of IL-10 is also dependent on 
other cytokines and immune activation, which links IL-10 genetic polymorphisms 
to T cell distributions and immune activation among HIV positive and HIV 
exposed individuals (Groux et al., 1998; Santin et al., 2000). 
In addition to HIV infection, IL-10 levels increase during multiple other 
persistent viral infections, such as chronic HBV and HCV infection (Cheong et 
al., 2006; Ejrnaes et al., 2006; Paladino et al., 2006; Wilson and Brooks, 2011). 
Although the results are still controversial, depending on the study groups and 
hepatitis stage analyzed (self-limiting, chronic, and occult), more data confirms 
the beneficial effect of low IL-10 protein production in fighting HBV and HCV 
infections (Cheong et al., 2006; Edwards-Smith et al., 1999; Ramezani et al., 2012; 
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Shin et al., 2003). For example, a meta-analyses of multiple ethnical groups 
showed that –592A is associated with spontaneous HCV recovery and –1082G 
with increased risk of chronic HCV infection (Sun et al., 2013). However, these 
results were highly dependent on the ethnicity of the specific study group. As the 
influence of IL-10 polymorphisms in HBV and HCV progression clears, the 
effects of these polymorphisms to hepatitis susceptibility remain poorly studied. 
The current study showed a beneficial effect of –592A to remaining HBV sero-
negative, but no differences were observed in relation to HCV infections. Similar 
studies could be conducted among populations of other ethnicities and risk 
groups, to further evaluate the effect of IL-10 polymorphisms on hepatitis 
susceptibility. 
 
 
6.5. T cell distribution and HIV, HBV, and HCV infections 
Similar to genetic studies, data regarding T cell responses among PWID subjects 
is limited, especially among ESN. Only a few studies have focused on T cell 
subsets, CCR5 expression, and immune activation among PWID (Markowitz et 
al., 2016; Tran et al., 2006). The study showed that PWID exhibit increased 
immune activation, increased numbers of CD45RA+RO+ cells, and lower 
densities of CCR5 on multiple T cell populations, compared to controls. 
Although PWID are – additionally to HIV – exposed to other infections and 
illicit drugs, most of the influences on T cell distribution are similar between 
sexual and parenteral HIV exposure (Biasin et al., 2000; Killian et al., 2004; Lo 
Caputo et al., 2003; Messele et al., 2001; Restrepo et al., 2010; Suy et al., 2007; 
Yang et al., 2002). The one exception to these similarities, was the number of 
CCR5+ cells and or CCR5 expression of T cells. The current study showed that 
both ESN and HIV positive individuals had lower CCR5 expression on T cells 
than controls. In contrast, numbers of CCR5+ cells increase during sexual HIV 
exposure (Suy et al., 2007). However, Tran et. al (2006) found decreased numbers 
of CCR5+ cells among Vietnamese PWID, which suggests that in addition to 
HIV exposure, CCR5 expression is affected by drug use.  
There has been much debate about the differences in T cell percentages and 
immune activation seen among ESN, and two possible hypotheses have been 
proposed. First, that the alterations in T cell distribution are the result of HIV 
exposure. Second, these alterations – compared to blood donors – represent an 
individual’s normal state of protection against HIV infection (Suy et al., 2007). 
As shown by Suy et al (2007), the increases in immune activation and memory 
cell subsets depends on the HIV positive partner’s viral load, i.e. seems to be a 
result of viral exposure, which also supports the first hypothesis. These are inde-
pendent of the route of exposure and correlate with the level of exposure (Suy et 
al., 2007). CCR5 expression might follow a different trend, as low CCR5 
expression of T cells may give an advantage in remaining HIV negative, and 
during HIV infection slow the progression of the disease (Reynes et al., 2001). 
Multiple other studies have shown T cell subset changes during HBV and HCV 
infections, however, these studies have focused on acute or chronic infections, not 
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seropositivity (Appay et al., 2002; Appay and Rowland-Jones, 2004; He et al., 
1999; Urbani et al., 2005). The current study found only one difference in CD4+ 
percentages and analyzing the stages of hepatitis infections in larger groups 
might reveal additional differences in memory cell subset distributions or immune 
activation. The effect of this small CD4+ decline is not yet known, but it might 
influence an individual’s overall immune response. In addition to T cell 
distribution, multiple other factors apparent in co-infected individuals must be 
taken into account. These factors include cytokine profile and virus-specific T 
cell responses.  
 
 
6.6. T cell distribution and intravenous drug use 
In addition to HIV, HBV, and HCV infections, the effect of IVDU on T cell 
distribution was evaluated. The current study showed a decrease in CD4+ TEM 
cells, and an increase in percentages of CD8+ TCM cells, immune activation, and 
the number of CCR5+ cells among triple negative PWID compared to controls. 
There are not many studies that have analyzed the effect of illicit drugs on the 
immune system from PWID blood samples.  
Opioids, such as fentanyl, are commonly used by Estonian PWID (Uusküla et 
al., 2010). Opioids are usually regarded as immunosuppressive, thus the increase 
in immune activation and memory T cells found during the current study can be 
regarded as somewhat contradictory. However, these suppressive mechanisms 
are very complex, acting via T cell response, opioid receptors, and cytokines 
(Barcellini et al., 1995; Börner et al., 2009; Mahajan et al., 2005). For example, 
opioids can inhibit IL-6 production and even IL-2 production in activated T cells 
(Börner et al., 2009; Roy et al., 2004). Increased numbers of immune activated 
cells therefore do not reflect the overall immune response or levels of anti-
inflammatory cytokines.  
Our results showing an increase in CCR5+ cells complement earlier studies of 
cell culture and animal models that indicated an increase due to opioid exposure 
(Li et al., 2002; Platt et al., 2016; Steele et al., 2003; Wang et al., 2003; Wang et 
al., 2011). As CCR5 and immune activation markers are expressed on the same 
cells, further research is needed to determine if the increase in CCR5+ expression 
is caused by opioids or by an increase in HLA-DR. However, it is not possible to 
rule out that these changes were owing to viral exposure (e.g. HIV, HBV, and or 
HCV) and further studies are needed to clarify CCR5 expression among PWID.  
 
 
6.7. Future research 
The current study investigated relationships between IL-10 polymorphisms and 
T cell distribution, HIV, HBV, and HCV infections, and IVDU. The results 
showed that IL-10 genetic polymorphisms may influence susceptibility to HIV 
and HBV. No effect was not seen among HCV exposed seronegative subjects. 
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One reason for this could be the small size of the HCV exposed seronegative 
group. An additional analysis with more HCV exposed individuals could reveal 
an effect of IL-10 genetic polymorphisms on susceptibility to HCV. It would be 
interesting to analyze the effect of additional interleukin polymorphisms (such as 
IL-2, IL-6, and IL-12) on susceptibility to the infections, because as in the case 
of IL-10, data regarding polymorphisms among PWID populations are almost 
entirely absent. Among sexually exposed populations, these polymorphisms 
have an impact on susceptibility to HIV susceptibility and or its progression.  
Of T cell subpopulations, data regarding the influence of the stage of HIV, 
HBV, and HCV infections on T cell distributions remains insufficient. Not much 
research has been carried out among PWID, whose immune system is influenced 
by repeated exposure to multiple viruses and opioids. A new prospective study 
analyzing the effects of acute, self-limiting, and chronic hepatitis types and HIV 
disease stage could better describe the role of T cell changes and immune 
activation during the progression of each disease. Much more research is needed 
to further reveal the effects of opioid use on susceptibility to HIV, HBV, and 
HCV. 
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7. CONCLUSIONS 
1. The presence of at least one low IL-10 producing allele (–1082A or –592A) 
might protect highly exposed seronegative subjects (HESN) against HIV 
infection. Furthermore, the –592AC genotype and –592AC containing geno-
type pairs seem to protect against both HIV and HBV infections among PWID.  
2. HIV negative PWID who share needles and thus have likely been repeatedly 
exposed to blood-borne infections, including HIV, have altered T cell distri-
butions. More specifically, in comparison to people without this risk behavior, 
ESN PWID have increased immune activation and lower CCR5 surface 
density on CCR5+ T cells. This increase in immune activation seems to be a 
result of viral exposure, however, the differences in CCR5 expression density 
could be caused by intravenous drug use itself. 
3. HIV/HBV/HCV co-infected individuals demonstrate similar T cell changes to 
HIV mono-infected individuals, such as a decrease in percentages of CD4+ T 
cells, an increase in memory cell subsets, immune activation, and CCR5+ cell 
percentages. These changes are likely triggered by HIV infection; neither 
hepatitis viruses added to the immunosuppression caused by HIV. Among 
HBV/HCV seropositive individuals, only a limited drop in CD4+ cell per-
centages was observed, suggesting once again that seropositivity to HBV and 
or HCV has minimal effects on T cell distribution and also likely to immune 
disturbances in HIV positive subjects co-infected with hepatitis viruses.  
4. Triple negative PWID had lower percentages of CD4+ TEM, higher per-
centages of CD8+ TCM cells, and higher percentages of activated and CCR5+ 
cells among both CD4+ and CD8+ T cells compared to controls. This indicates 
that even while remaining seronegative for all the studied viruses, the immune 
systems of PWID are disturbed, likely as a consequence of injecting drugs 
and or exposure to various pathogens. 
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8. SUMMARY IN ESTONIAN 
Immunoloogiliste faktorite mõju HIV-i, B-hepatiidi ja C-hepatiidi 
viirustesse nakatumisele süstivate narkomaanide hulgas 
Inimese immuunpuudulikkuse viirus 1-ga (HIV) on maailmas nakatunud üle 35 
miljoni inimese ning aastal 2014 suri HIV tõttu 1,2 miljonit inimest. Lisaks HIV-
le põhjustavad terviseprobleeme ka B hepatiidi (HBV) ja C hepatiidi viirused 
(HCV). Kõigil kolmel viirusel on sarnased nakatumisteed ja selle tõttu on ka 
nende ko-infektsioonid tavalised. Eriti on ohustatud süstivad narkomaanid (SN). 
Eelnevad uuringud on leidnud, et mõned inimesed ei nakatu HIV viirusega 
hoolimata korduvast kokkupuutest. Selliseid inimesi nimetakse sageli kõrgelt 
eksponeeritud seronegatiivseteks isikuteks (KESN) või eksponeeritud seronega-
tiivseteks isikuteks (ESN). Põhiliselt on uuritud seksuaalsel teel viirusele ekspo-
neeritud isikuid ja uuringuid SN-ide seas on olnud vähe. Kuigi mitte nakatuvaid 
inimesi on uuritud epideemia algusaegadest saati, ei ole siiani teada nende resis-
tentsuse põhjuseid. Üheks põhjuseks võib olla HIV ko-retseptori CCR5 puudu-
mine rakkude pinnal, mida põhjustab 32-aluspaarine deletsioon CCR5 geenis. 
Samas kõik inimesed, kes ei nakatu HIV-ga, ei ole vastava mutatsiooni kandjad 
ja resistentsust võivad põhjustada mutatsioonid mitmetes teistes immuun-
süsteemi geenides (näiteks interleukiinide, HLA regiooni või CCR5 ligandide 
geenides). 
Lisaks geneetilistele polümorfismidele on ESN-ide seas uuritud ka mitmete 
teiste immunoloogiliste faktorite mõju. Näiteks on vaadeldud erinevate T raku 
populatsioonide muutumist viirusele eksponeeritud indiviididel ning on näi-
datud, et neil suurendab kokkupuude viirusega mälurakkude hulka veres. Samuti 
esineb eksponeeritutel rohkem immuunaktivativeeritud rakke. Sarnaselt geneetika 
uuringutele on vähe teavet süstivate narkomaanide kohta ja eriti mitmetele viirus-
tele eksponeerituse või ka HIV, HBV ja HCV ko-seropositiivsuse mõjude kohta T 
raku populatsioonidele. Lisaks on vähe teavet süstiva narkomaania mõjude kohta 
T raku jaotusele ja immuunsüsteemile ilma kaasuvate viirusnakkusteta.  
 
Uurimistöö eesmärgid 
Töö üldine eesmärk oli hinnata immunoloogiliste faktorite mõju HIV-i nakatu-
misele ja uurida, kuidas seropositiivsus kolme viiruse (HIV, HBV ja HCV) 
suhtes mõjutab T raku jaotust europiidsesse rassi kuuluvatel SN-idel. 
 
Uuringu alameesmärgid 
1. Kirjeldada kuidas ja kas IL-10 polümorfismid –1082 ja –592 mõjutavad HIV, 
HBV ja HCV-ga nakatumist. 
2. Kirjeldada seoseid HIV ekspositsiooni, CCR5 ekspressiooni, immuunaktivat-
siooni ja T rakkude jaotuse vahel SN-ide populatsioonis. 
3. Kirjeldada seoseid HIV, HBV ja HCV ko-infektsioonide, CCR5 ekspressiooni, 
immuunaktivatsiooni ja T rakkude jaotuse vahel SN-ide populatsioonis. 
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4. Kirjeldada seoseid süstiva narkomaania, CCR5 ekspressiooni, immuunakti-
vatsiooni ja T rakkude jaotuse vahel SN-ide populatsioonis. 
 
Uuritavad ja metoodika 
Uuring viidi läbi kahes osas.  
1. Esimesse uuringusse kaasati 345 SN-i ja 496 tervet vabatahtlikku vere-
doonorit. Veredoonorite demograafilised andmed ei olnud teada. SN-idest 
79% olid mehed ja uuritavate mediaanvanus oli 30 aastat. SN-idest 20 olid 
viimase kuu aja jooksul kasutanud süstalt, mida oli eelnevalt kasutanud keegi 
teine. Need 20 uuritavat klassifitseeriti KESN-ideks. SN-id värvati 2011. 
aastal Tallinna süstlavahetuspunktidest. 
2. Teise uuringusse kaasati 88 SN-i (eelmise uuringu 345-st), kellest 41 olid 
HIV positiivsed SN-id ja 47 HIV negatiivsed (viimase kuue kuu jooksul jaga-
nud süstalt) SN-id. Kontrollgrupina kaasati 47 tervet vabatahtlikku, kes olid 
soo ja vanuse alusel sarnased ESN-idele.  
 
Kõikidelt uuritavatelt koguti veri EDTA katsutitesse ja täisverest eraldati 
perifeerse vere mononukleaarsed rakud. IL-10 polümorfismide määramiseks eral-
dati rakkudest inimese genoomne DNA ja IL-10 polümorfismid määrati Real-
Time PCR-iga, kasutades Allelic Dicrimination Assay’d. 
T rakkude jaotuse määramiseks kasutati läbivoolutsütomeetriat. Perifeerse 
vere mononukleaarsed rakud värviti fluorokroomidega konjugeeritud 
antikehadega (8 pinnamarkerit: CD3, CD4, CD8, CD45RA, CD45RO, CCR7, 
HLA-DR ja CCR5 jaoks) ning seejärel fikseeriti. Fikseeritud rakke analüüsiti 
LSR Fortessa voolutsütomeetril. 
Statistilises analüüsis kasutati geneetiliste polümorfismide analüüsil Fischeri 
täpset testi ja T rakkude populatsioonide analüüsimisel Wilcoxoni testi. 
 
Peamised tulemused ja arutelu 
Kõikides gruppides olid IL-10 alleelid –592C ja –1082A kõige sagedasemad ja 
1082AG/–592CC levinuim genotüübi paar. Kõikidel KESN-idel oli vähemalt üks 
–1082A alleel, samas kui HIV positiivsetel SN-idel oli 81,4% ja doonoritest 79% 
vastav alleel (vastavalt p=0,029 ja p=0,019). KESN-idel ei olnud GG/CC geno-
tüübi paari, kuid see esines 18,6% HIV positiivsetel SN-idel ja 21% doonoritel 
(vastavalt p=0,029 ja p=0,019). HBV nakkuse puhul vähendasid –592AC alleel ja 
AG/AC genotüübi paar šansse HBV-ga nakatuda (vastavalt OR=0,28; 95% CI 
0,09–0,87; p=0,028 ja OR=0,19; 95% CI 0,06–0,61; p=0,052). Kokkuvõttes võib 
öelda, et alleelid, millelt ekspresseeritakse vähe IL-10 (–1082A and –592A) 
kaitsevad sageli eksponeeritud isikuid HIV ja HBV infektsioonidega nakatumise 
eest. 
Voolutsütomeetriline analüüs näitas, et ESN-idel on suurenenud immuun-
aktivatsiooni tase (rohkem HLA-DR+ rakke), rohkem CD4+ CD45RA+RO+ ja 
CD8+ CD45RA+RO+ rakke võrreldes tervete vabatahtlikega. Kuigi kõikide 
uuringugruppide CCR5+ rakkude protsendid olid sarnased, oli CCR5 tihedus 
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raku pinnal ESNidel madalam kui tervetel vabatahtlikel. Siit järeldub, et süstiv 
narkomaania võib mõjutada CCR5 ekspressiooni.  
Analüüsides HIV+HBV+HCV+ kolmikpositiivseid SN-e (n = 35) oli näha, et 
neil on vähem CD4+ rakke ja rohkem immuunaktiveeritud rakke kui HIV nega-
tiivsetel SN-idel (p < 0,001 kõikidel juhtudel). HBV+HCV+ SN-del oli väiksem 
CD4+ rakkude protsent kui kolmiknegatiivsetel SN-del (52,1% ja 58,6%, 
p = 0,021). Võrreldes omavahel kolmiknegatiivseid SN-e ja terveid vabatahtlikke 
selgus, et esimestel on kõrgem immuunaktivatsioon ja rohkem CCR5+ rakke. 
Kokkuvõttes võib öelda, et HIV positiivsetel on põhiliseks immuunsüsteemi 
mõjutajaks HIV ja lisanduvad ko-infektsioonid (HBV ja HCV) T rakkudele suurt 
lisamõju ei avalda. Samas HBV+HCV+ kaksikinfektsiooni korral vähendavad 
infektsioonid CD4+ rakkude hulka. 
Analüüsimaks süstiva narkomaania mõju T rakkudele, võrreldi kolmiknega-
tiivseid SN-e (HIV–HBV–HCV–) tervete vabatahtlikega. Uuringus selgus, et 
kolmiknegatiivsetel SN-idel on vähem CD4+ TEM rakke, rohkem CD8+ TCM 
rakke, rohkem immuunaktiveeritud rakke ja rohkem CCR5+ rakke võrreldes 
tervete vabatahtlikega.  
 
Järeldused: 
1. SN-e kaitsevad HIV nakkuse eest IL-10–1082A ja –592A alleelid ning 
HIV ning HBV nakkuste eest –592AC genotüüp koos –592AC-d sisaldavate 
genotüübi paaridega. 
2. Sarnaselt viirusele seksuaalsel teel eksponeeritud isikutele, on SN ESN-idel 
kõrgenenud immuunaktivatsioon ja kõrgenenud CD45RA+RO+ rakkudeprot-
sent võrreldes tervete vabatahtlikega. Lisaks on SN ESN-idel madalam CCR5 
pinnatihedus kui tervetel vabatahtlikel.  
3. HIV+HBV+HCV+ SN-idel on sarnased T raku muutused (kõrgenenud 
immuunaktivatsioon, mälurakkude hulk ja CCR5 ekspressioon) kui HIV 
monoinfektsiooniga indiviididel. HBV+HCV+ kaksiknakkusega SN-idel on 
ainult väiksem CD4+ rakkude arvukus, mis näitab, et HBV ja/või HCV 
seropositiivsusel on vähene mõju T raku jaotusele.  
4. HIV–HBV–HCV– SN-idel on muutunud mälurakkude jaotus, kõrgem 
immuunaktivatsioon ja rohkem CCR5+ rakke võrreldes tervete vabatahtlikega. 
Seega mõjutab ka süstiv narkomaania HIV, HBV ja HCV nakkusest hooli-
mata T rakkude jaotust. 
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